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Abstract 1 
Passive exposure to cannabis smoke may induce effects on behavior and psychomotor skills, 2 
and have legal consequences, including the risk of being falsely considered as a cannabis user. 3 
This can become a concern, especially in occupational contexts or when driving vehicles. In 4 
order to enable a differentiation between a passive and an active exposure to cannabis and to 5 
limit the likeliness to be detected positive following passive exposure, this review identified 6 
specific biomarkers of passive exposure in urine, blood, oral fluid, hair, and sebum. Out of 958 7 
papers identified on passive exposure to cannabis, 21 were selected. Although positive tests 8 
had been observed in all matrices following extremely high passive exposure, some distinctive 9 
features were observed in each matrix compared to cannabis active use. More specifically, in 10 
everyday life conditions, 11-nor-delta-9-THC-carboxylic acid (THC-COOH) urinary level should 11 
be detected below the positivity threshold used to confirm active smoking of cannabis, 12 
especially after normalization to creatinine level. Measuring delta-9-tetrahydrocannabinol (THC) 13 
and THC-COOH in blood is an appropriate alternative for appraising passive exposure as low 14 
and very low concentrations of THC and THC-COOH, respectively, should be measured. In hair, 15 
oral fluid (OF) and sweat/sebum emulsion, no THCCOOH should be detected. Its presence in 16 
hair argues for regular cannabis consumption and in OF or sweat for recent consumption. The 17 
experts should recommend to persons who have to demonstrate abstinence from cannabis to 18 
avoid heavily smoky and unventilated environments. 19 
 20 
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1 
Introduction 23 
Cannabis passive smoking referred to the inhalation of cannabis smoke, called secondhand 24 
smoke or environmental cannabis smoke, by persons other than intended "active" smokers. It 25 
occurs when cannabis smoke contaminates any environment and it is inhaled by people staying 26 
in that environment. Secondhand smoke is defined as the combination of the sidestream smoke 27 
released from a burning end of a marijuana cigarette and the mainstream smoke exhaled by a 28 
smoker [1]. Besides inhalation, unintentional cross-contamination could also occur by 29 
unintended direct contact with contaminated objects, as illustrated in Figure 1. Hence, cannabis 30 
smoke can be swallowed or deposited on hair, skin, clothes, and surrounding surfaces (e.g., 31 
furniture, doorknobs or water taps) [2]. This type of pollution is called thirdhand smoke [3]. 32 
However, the cross-contamination and exposure of non-smokers should happen less frequently 33 
than self-contamination, despite the fact that residual cannabinoids may build up on surfaces 34 
over time and resist normal cleaning and airing out [4]. Lastly, cannabis derivatives may be 35 
accidentally ingested with contaminated food. 36 
Several studies evidenced detectable concentrations of cannabinoids in body fluids following 37 
exposure to secondhand cannabis smoke [5-23]. For instance, the recent studies by Herrmann 38 
et al. [10] and Cone et al. [8; 9] confirmed that passive exposure to cannabis smoke under 39 
extreme exposure conditions not only resulted in measurable cannabinoid concentrations in oral 40 
fluid, blood, and urine, but also in minor physiological (increased heart rate) and subjective drug 41 
effects, as well as minor impairments in a task requiring psychomotor ability and working 42 
memory. This exposure could be very common (e.g., one partner smoking marijuana, to sit in a 43 
car or stay at home with one or several smokers). 44 
Passive exposure to cannabis is furthermore a significant legal issue, and it may be especially 45 
so in occupational contexts and when driving vehicles. In the workplace, passive exposure 46 
should not be mistaken for active use if it might lead to sanctions against employees. With 47 
regard to driving, active and regular cannabis consumption should not be mistaken for 48 
unintended frequent passive exposure. In cases of acute exposure and a zero-tolerance driving 49 
policy, a THC-positive blood specimen may well result in the same legal and administrative 50 
consequences, regardless of whether exposure was active or passive. In the forensic and 51 
medical contexts, differentiating passive, unintentional exposure to cannabis remains an issue 52 
of how to interpret the results of body fluid analyses. 53 
Most experimental studies assessing the importance of passive contamination to environmental 54 
cannabis smoke were carried out with abstinent volunteers enclosed in an exposure chamber. 55 
2 
Many parameters were controlled as the smoke density, the cannabinoid concentrations, or the 56 
duration of exposure. From these studies, the present review summarizes findings obtained until 57 
December 2015, and discusses the relevance of the different biomarkers available for diagnosis 58 
of passive exposure versus active use. More specifically, it describes the current state of 59 
knowledge on the passive inhalation of cannabis, and the consequences of an external 60 
contamination of body surfaces on the results from tests of biological samples (urine, blood, oral 61 
fluid, hair, and sebum/sweat). The specific biomarkers and decision limits, or positivity 62 
thresholds, that can help differentiate between active consumption and passive exposure will 63 
particularly be discussed from a legal and forensic perspective. After a short presentation of the 64 
most important factors affecting the cannabis contamination, the selection strategy of the 65 
relevant scientific literature will be described. The paper will afterwards consider the important 66 
elements (i.e., analytical methods, concentration ranges, contamination, and interpretation) in 67 
result interpretation of each biological fluid and tissue following passive exposure to cannabis. 68 
This review article is mainly intended for forensic experts who are confronted with statements of 69 
passive contamination or for persons frequently exposed and worried by passive cannabis 70 
smoke. This article should allay some of their concerns and facilitate the work of expertise of 71 
forensic experts. 72 
 73 
Cannabinoids: metabolism in human 74 
The plant precursor to THC is delta-9-tetrahydrocannabinolic acid A (THC-A) [24]. THC-A itself 75 
has no psychotropic effect and should be considered as a pro-drug. The main active 76 
cannabinoid responsible for the psychoactive properties of cannabis is THC [25]. The thermal 77 
decarboxylation of THC-A to THC is only partial when cannabis is smoked [26] or rarely 78 
complete when heated in an oven. Although it is mainly inhaled, cannabis can also be 79 
consumed in food and beverages. As medicine, cannabis is generally not smoked (but can be 80 
vaped); the risk of passive contamination is thus very low. 81 
Cannabinoids can be absorbed by respiratory airways and to a lesser extent by oral route. The 82 
dermal route was reported to be minor; therefore, a passive contamination by this route seems 83 
unlikely [27]. After inhalation, THC is rapidly absorbed from the lungs into the bloodstream. It is 84 
metabolized by liver enzymes or distributed to adipose tissue, the lungs, and spleen due to its 85 
high lipophilicity [25]. In the liver, THC is oxidized mainly into 11-hydroxy-delta-9-THC (11-OH-86 
THC) and then into 11-nor-delta-9-THC-carboxylic acid (THC-COOH) [28]. THC-COOH is 87 
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further rapidly conjugated to glucuronic acid, forming the ester-link glucuronide (THC-COOH-88 
glucuronide). THC is slowly released from the body’s lipid-storage compartments. THC’s 89 
plasmatic terminal half-life is estimated at 1 to 6 h for infrequent users and 20 to 36 h for 90 
frequent users [29-31]. THC is eliminated slowly, mainly in the form of acid metabolites, and its 91 
main disposal route is via feces (60%–80%); the urine route is less important (20%–35%). In 92 
urine, the main metabolite excreted is THC-COOH-glucuronide. Only a small amount of free 93 
THC-COOH is excreted (< 4%), along with only traces of THC. The urinary excretion half-life of 94 
THC-COOH was estimated at 30 h by Musshoff and Madea [25] to 3 to 4 days by Huestis et al. 95 
[30], depending on cannabis conditions of use. 96 
 97 
Cannabis smoke 98 
Overall, it is the smoking of cannabis cigarette that raises a number of questions regarding the 99 
passive exposure to cannabinoids, and more specifically to THC. In an attempt to estimate 100 
inhaled THC doses and to determine an internal dose, some studies monitored THC levels in air 101 
[5-7; 14; 18; 19]. It is assumed that the smoking process itself degrades 23%–30% of the total 102 
THC content in cannabis by pyrolysis, and some 20%–37% is delivered to the active user in 103 
mainstream smoke. The remaining 40%–50% of THC is released to the environment in 104 
sidestream smoke [18; 25; 32; 33]. Consequently, despite the high influence of several factors 105 
on the rate of absorption, a notable amount of THC can still be inhaled by passive smokers and 106 
then be absorbed, metabolized, and excreted just like an active user. 107 
Until recently, few investigations have been carried out to characterize the components of the 108 
smoke from marijuana cigarettes, and the majority of these concentrated on analyzing the 109 
cannabinoids in smoke, as they are the most biologically active constituents of cannabis [34]. 110 
Cannabis smoke is composed of gas and particulate phase substances. Cannabinoids are 111 
mainly found in the particulate phase [35]. This smoke is diluted in the environment, and low but 112 
notable concentrations of THC and other cannabinoids can be measured in several urban areas 113 
[36; 37]. 114 
 115 
Influence of experimental conditions 116 
The studies on passive exposure to cannabis smoke clearly evidenced the importance of the 117 
different factors influencing the results and their interpretation. In 1983, Falck [38] highlighted 118 
the many factors influencing concentrations of urinary cannabinoids: amounts of water drunk 119 
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before urine collection, the rate of urine formation, metabolic rate, the quantity of urine voided, 120 
and the time of marijuana absorption or urine voiding. Similarly, Cone and Johnson [5] pointed 121 
out that plasma levels and the presence of urinary metabolites depended on a variety of factors, 122 
including duration and frequency of exposure to smoke, cannabinoid concentrations in the 123 
room’s air, and individual sensitivity to marijuana. According to Moffat [31], the most important 124 
factors influencing body fluid concentrations were: smoking techniques (i.e., THC content, room 125 
size, ventilation, exposure time, the number of smokers in the room, the time between exposure 126 
to passive smoke and urine collection, and urine hydrolysis to obtain the free acid in order to 127 
increase the sensitivity of metabolite detection. Busuttil et al. [39] added dose (the amount of 128 
THC released in smoke), body weight, age, sex, renal and hepatic function, and the analytical 129 
techniques used as factors affecting the detection of THC and its metabolites in blood and urine. 130 
Furthermore, the studies by Niedbala et al. [17-19] confirmed that the detection of THC-COOH 131 
in urine (in free and conjugated forms) is affected by a multitude of pharmacological and 132 
physiological factors (i.e., THC content of marijuana, dose uptake, sampling time, individual 133 
renal and metabolic characteristics, body size). In addition, methods of cannabis inhalation can 134 
also modify exposure levels for non-smokers [40]. 135 
 136 
Biological markers and decision limits as criteria of passive exposure 137 
Since 1977, several authors have studied passive exposure to cannabis smoke in order to 138 
better interpret analytical results and to validate the decision limit or positivity threshold fixed by 139 
different scholarly societies (see Table 1). However, as no standard definition of “passive 140 
inhalation” exists, concerns remain to diagnose active use or passive exposure based simply on 141 
levels in body fluids [39; 41]. From a forensic viewpoint, Busuttil et al. [39] defined passive 142 
exposure as “the presence of cannabinoids in the body fluids of non-users who have been 143 
passively exposed to marijuana smoke”. The authors pointed out that any person who allows 144 
himself to be deliberately exposed to cannabis smoke—at high dosages, for long durations, and 145 
in a confined space, so as to absorb enough THC for metabolite levels to be measured at over 146 
100 ng/mL in urine (total THC-COOH, without correction for creatinine) or 25 ng/mL in plasma 147 
(free THC-COOH)—must be a “willing participant” and knowingly aware of the potential effects 148 
[39]. Consequently, the concept of passive exposure involves unintended contamination. 149 
Moreover, THC in sidestream smoke is mainly released as aerosol particles and their 150 
concentration is rapidly and heavily diluted with the flow of surrounding air [19]. It remains that 151 
over the last few decades, the levels of THC in plants have raised substantially, mainly due to 152 
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the expansion of indoor cultivation and the selection of varieties that maximize THC yields [8; 153 
29] (e.g., the average potency of all types of cannabis was 13.2% in 2012 vs 2.8% and 7.3% for 154 
marijuana and sinsemilla, respectively, in 1985 in the US [8], and remained unchanged for 10–155 
20 years, consistently 2%–8%, to reach more than 10% in Europe [42]). Consequently, the 156 
higher the potency of the cannabis is, the greater the potential risk of positive body fluid test 157 
results after passive exposure. 158 
 159 
Selection strategy of references 160 
Several library databases were used to identify and select publications dealing with passive 161 
exposure to cannabis (i.e., PubMed, Medline Ovid SP, Embase, Cochrane Library Wiley, 162 
Cinahl, Web of Science and Google Scholar). Only papers published after 1970 and before 163 
August 2015 were considered. Different terms and research strategies were combined (see 164 
supplementary data for the combinations of search terms used). The selection was based on 165 
titles and abstracts, and papers in English, French, German, and Italian were considered. The 166 
initial investigation identified 958 papers; after removing duplicates and considering the 167 
suitability and appropriateness of titles, 98 abstracts were reviewed. Of these, 77 papers did not 168 
fulfill the criteria for eligibility. These criteria included only studies on exposure to passive 169 
cannabis smoke in controlled conditions, collecting biological matrices in non-users volunteers, 170 
and reporting results on matrix analysis. A final total of 21 studies on passive exposure to 171 
cannabis were selected. In agreement with Moffat [31], the authors of this review considered 172 
that the most important factors in each study were: 173 
1. Volume of the exposure room and its ventilation characteristics (e.g., opening a 174 
door or window can reduce the concentration of THC in the air); 175 
2. Number of non-smoker volunteers exposed to passive inhalation of cannabis; 176 
3. Exposure time and exposure conditions for the non-smoker volunteers; 177 
4. Magnitude of exposure (e.g., number of marijuana cigarettes smoked, dose of 178 
THC); 179 
5. Analytical methods used to detect the cannabinoids and their metabolites in body 180 
fluids and tissues. 181 
The 21 publications included in the present study are summarized in Supplementary Tables 1 182 
and 2. 183 
 184 
6 
Biological samples: methods of analysis, concentration ranges after passive exposure 185 
compared to active use, result interpretation, and decision limits 186 
Environmental exposure to cannabis smoke can be detected and analyzed in urine, blood, oral 187 
fluid, hair, and sebum/sweat. Each biological specimen provides different information regarding 188 
the drug’s effects on health, performance, behavior, and on the individual’s drug-exposure 189 
history. Likewise, each matrix has its specificities with regard to interpreting cannabis exposure, 190 
offering different advantages and disadvantages for drug testing. Figure 2 summarizes the main 191 
potential markers present in the different biological matrices, as well as their excretion routes 192 
following the involuntary exposure to cannabis. 193 
 194 
Urine 195 
Urine remains the matrix of choice for drug-testing programs to demonstrate past drug exposure 196 
in workers or drivers because of the long time detection of THC-COOH and its conjugated 197 
metabolite in urine. One of the major advantages of using urine as a matrix is the ease to collect 198 
spot samples at any time (determined collection time or ad libidum collection) from an analytical 199 
point of view. However, urine samples imply large variability in volume and, consequently, in 200 
chemical concentrations from void to void [43]. In addition, urine samples can be falsified by 201 
dilution, substitution, or adulteration using a wide array of substances. 202 
 203 
Analysis 204 
Urine is mainly analyzed using immunoassays and chromatography coupled to mass 205 
spectrometry methods. Regarding immunoassays, improvements in method sensitivity and 206 
specificity as well as more appropriate enzymes allowed selection of a lower cut-off to 207 
distinguish active from passive smoking and to develop a less invasive body fluid collection. As 208 
illustrated in Table 2, the enzyme multiplied immunoassay technique (EMIT) was first commonly 209 
used, but the labeling of antibodies was changed to decrease the limit of detection (LOD) value, 210 
and EMIT was replaced by 125I-radioimmunoassay (RIA, 2 ng/mL) or enzyme-linked 211 
immunosorbent assay (ELISA, 0.6 ng/mL). RIA had the advantage that no cross-reaction with 212 
other compounds than cannabinoids related to Δ8 or Δ9 was observed, reducing the risk of 213 
false positive results [13; 31]. Although immunoassays are considered as suitable methods for 214 
cannabinoids screening, some limits are recognized, such as cross-reaction with related and 215 
unrelated compounds (inducing false-positive results) or generation of artifacts in the presence 216 
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of adulterants affecting matrix pH, presence of detergents or surfactants (inducing false-217 
negative results) [25; 29]. Therefore, immunoassays are commonly adopted as a preliminary 218 
test method while mass spectrometry based methods are currently used to confirm cannabinoid 219 
identity and assess cannabinoid levels [25; 31]. Nowadays, the single chromatography coupled 220 
to mass spectrometry (GC-MS) methods are replaced by two-dimensional gas-chromatography 221 
high resolution mass spectrometry methods or ultra high performance liquid chromatography 222 
interfaced with atmospheric pressure ionization coupled with tandem high resolution mass 223 
spectrometry (LC-MS/MS). This last method short-circuits the extraction step and allow the 224 
direct analysis of free THC-COOH and its glucuronide conjugates in urine [44]. In contrast, GC-225 
based methods require the hydrolysis of conjugates and a derivatization step before analysis. 226 
Results are expressed as total THC-COOH (free plus conjugated). 227 
The best means of reducing drug measurement variability is to normalize cannabinoid 228 
concentrations to the urinary creatinine level. The normalization also allows the monitoring of 229 
abstinence from cannabis use and reduces false-positive or false-negative drug tests, especially 230 
during the late elimination phase when concentrations are either just above or below threshold 231 
values [30; 45-47]. Consequently, it is recommended to take into account the creatinine 232 
concentration for urinary THC-COOH although the decision limits or positivity thresholds are 233 
fixed without creatinine correction. In serial urine specimens, creatinine-normalized THC-COOH 234 
concentrations are also considered as better indicators to predict reuse of marijuana than 235 
without creatinine normalization [48]. 236 
 237 
Concentration ranges 238 
The detection of cannabinoids in urine indicates a past exposure to cannabis. However, urine 239 
gives no information related to the exposure route, the duration of exposure, or the amount of 240 
cannabis absorbed because of the long excretion half-life and the wide inter-individual variability 241 
[17; 30; 49]. Figure 3 summarizes the concentrations adjusted for creatinine of THC-COOH time 242 
profile in urine of different studies during and following a passive exposure to cannabis. Only 243 
studies analyzing urine by GC-MS and adjusting by creatinine were considered in Figure 3. 244 
Hence, in passive exposure studies, THC-COOH can be detected in urine around 1 h after 245 
exposure, and peak THC-COOH concentrations are observed at 6 to 8 h after exposure. 246 
Nevertheless, according to Westin and Slordal [49], any measurement of THC and THC-A, or of 247 
cannabinoids above the limit of quantification (15 ng/mL for THC-COOH, without correction for 248 
creatinine) in the urine of passive smokers must be related to such an extremely high exposure 249 
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that the person concerned could not be unaware that smokers in the immediate vicinity were 250 
smoking cannabis. Figure 3 supports a limit value of 15 ng/mg of creatinine for THC-COOH; 251 
higher values were obtained in extremely high exposure conditions. As no mandated creatinine-252 
normalized thresholds are available, Schwilke et al [48] have developed empirically derived 253 
statistical models using limit concentration values of 15 and 6 ng/mg creatinine as cutoffs to 254 
distinguish abstinence from new cannabis use in chronic smokers. These cutoffs are similar to 255 
the limit value observed in Figure 3. 256 
 257 
Interpretation 258 
The interpretation of urinary results is complex, and several factors may influence urinary 259 
concentrations of the main metabolite, THC-COOH-glucuronide. In addition to creatinine 260 
normalization, individual variability, and exposure conditions (cannabis dose and number of 261 
smokers, design of the room), the exposure room’s ventilation appears to be a relevant factor to 262 
consider. According to the study of Cone et al. [8], for the same inhaled dose of cannabis, total 263 
THC-COOH concentrations in the urine of passive non-smokers was two-thirds lower when the 264 
room was ventilated (median maximum concentration, or Cmax, of 24.9 and 8.5 ng/mL THC-265 
COOH (30.8 and 9.1 ng THC-COOH/mg creatinine, respectively) without and with ventilation, 266 
respectively). Cone et al. [8] also noticed similar differences for THC-COOH levels in the last 267 
collected urine specimen (4 ng/mL (6.7 ng THC-COOH /mg creatinine) versus 1.2 ng/mL (2.4 ng 268 
THC-COOH /mg creatinine) in a ventilated room, 31 h after exposure). In studies with 269 
ventilation, Cmax was found to be slightly delayed to 6 h, compared to the 4 h observed in 270 
studies with poor or no ventilation (see Figure 3). Besides ventilation effects, the range of THC 271 
concentrations has been correlated with the potency of marijuana cigarettes. Elimination time 272 
profiles shifted to greater concentrations when potency or dose was increased, but their time-273 
appearance remained very similar across the whole experiment. Consequently, urinary 274 
concentrations are mainly dose-dependent [12]. Further, the choice of the positive threshold 275 
value and the screening test characteristics will greatly influence the rate of positive sample 276 
detection. Hence, Cone et al. [8] found that increasing the immunoassay cut-off from 20 ng/mL 277 
to 50 ng/mL significantly decreased the rate of positive presumptive urine tests in non-smokers. 278 
At a 50 ng/mL cut-off, all but one of the immunoassays included in the experiment provided 279 
negative results. In summary, urine is an appropriate matrix to monitor abstinence from 280 
cannabis after creatinine normalization, even after moderate second-hand smoke exposure. In 281 
extreme conditions, THC-COOH may be detected in urine after passive exposure to cannabis 282 
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smoke. However, ventilation strongly attenuates the likelihood of being tested positive, and 283 
urinary concentrations of cannabinoids are greatly influenced by the potency of the marijuana 284 
and the dose. 285 
Blood 286 
Blood analyses are necessary for the detection of recent exposure to cannabis or for the 287 
evaluation of its effects on behavior and performance [9; 10]. In general, as THC is extensively 288 
bound to lipoproteins, the preferred specimens for blood analyses are plasma or serum. The 289 
two main metabolites considered as detectable in blood specimens after passive exposure are 290 
THC-COOH and its glucuronide ester conjugate [39]. 291 
 292 
Analysis 293 
The majority of passive exposure experiments involving THC measurements in plasma were 294 
performed in the 1980s. At that time, blood analyses were carried out using a 295 
radioimmunoassay or, less frequently, single-quadrupole gas chromatography–mass 296 
spectrometry (GC-MS). RIA was the main radioimmunoassay method for plasmatic THC 297 
determination (cutoff of 3 ng/mL). However, due to cross-reactions of antibodies with 298 
metabolites in a radioimmunoassay, it is difficult to compare these estimates with the results 299 
obtained using modern mass spectrometry techniques. As for urine, immunoassays are 300 
considered as a preliminary test method and results have to be confirmed using mass 301 
spectrometry based methods. However, highly sensitive and accurate methods are required to 302 
detect and quantify the low blood concentrations of THC observed during the late time course of 303 
drug effects due to THC’s rapid distribution to bodily tissues and to the time delay between 304 
exposure and sample collection [30; 50; 51]. Hence, more recently, Röhrich et al. [22] and Cone 305 
et al. [9] used more sophisticated mass spectrometry assays (e.g., liquid chromatography 306 
interfaced with tandem MS) either with serum or whole blood, and managed to extend the time 307 
since exposure in which cannabinoids can be measured accurately (Table 2). 308 
To accurately compare concentrations detected in blood specimens, the distribution ratio of 309 
cannabinoids between plasma or serum and whole blood should also be considered. A mean 310 
plasma to whole blood ratio of 1.6 has been suggested for both THC and THC-COOH [52]. 311 
Nonetheless, contrary to urine with creatinine, normalization with hematocrit is hardly ever done 312 
for blood, serum, or plasma. Hematocrit values are systematically ignored, although they vary 313 
substantially between whole blood specimens. Likewise, the small fraction of free cannabinoids 314 
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ables to bind to brain receptors and to induce the typical effects of cannabis is never evaluated 315 
either. Nevertheless, with the recent development of deuterated homologs and specific 316 
quantification methods, it is now possible to analyze free and conjugated cannabinoids 317 
separately. These two values should therefore be quantified to give a better interpretation of 318 
results. 319 
 320 
Concentration ranges 321 
Cannabinoid kinetics in blood are complex and difficult to interpret. Figure 4 summarizes the 322 
concentrations of THC (a) and THC-COOH (b) time profile in blood of different studies during 323 
and following a passive exposure to cannabis. The results of Morland et al. [15] showed that the 324 
highest levels of plasmatic THC were measurable immediately after the three volunteers had 325 
been exposed to 30 min of secondhand smoke generated by two smokers in a small car. 326 
Despite only two sampling times in this study, it can be assumed that the levels of plasmatic 327 
THC measured in blood just after leaving the car were close to the maximum values, as it has 328 
been observed in more recent studies (Figure 4a). At 2 h, THC levels had decreased to 329 
insignificant values. However, the use of low-potency marijuana cigarettes (1.5% THC) highly 330 
limits the relevance of this study today. Currently, cannabis is far more potent, and the 331 
composition of the different cannabinoids in cannabis plants has diversified. For instance, some 332 
plant strains may be characterized by a high proportion of THC and cannabidiol (CBD) (e.g., 333 
10% THC and 15 % CBD), whereas others have a high content of tetrahydrocannabivarin 334 
(THCV). THCV is a THC variant with short C3 lateral chain reported to have psychoactive 335 
properties at high doses (e.g., Perplex Feminized Seeds marketed by Seed Supreme) [53]. For 336 
the recent studies by Röhrich et al. [22] and Cone et al. [9], comparing Figures 4a and 4b 337 
reveals similar ranges of THC and THC-COOH concentrations, as well as similar Cmax (at Tmax 338 
between 20 to 60 min) for both compounds. Concurrent measurements of THC and THC-COOH 339 
in whole blood after passive exposure indicated a rapid absorption and metabolism of THC. 340 
However, Röhrich et al. [22] detected very low concentrations of THC and THC-COOH in 341 
passive smokers at the end of exposure. Indeed, they were so close to the analytical cut-off that 342 
calculation of their relative levels was irrelevant. The maximum THC concentration was 343 
observed at 90 min after the beginning of the exposure, and undetected 180 min after exposure 344 
to cannabis smoke. The exposure scenario conditions selected for non-smoker volunteers in 345 
this study seemed closer to real passive smoking conditions than the 1980s studies (e.g., large 346 
room, efficient ventilation, quite a long exposure time (3 h), and between 8 and 25 cannabis 347 
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users). In the study by Cone et al. [9], the range of reported Cmax levels over the three sessions 348 
was 0.5–3.1 ng/mL for THC and 0.2–2.5 ng/mL for THC-COOH at 0.25 h following the 1 h 349 
exposure session. As expected, higher Cmax were observed in unventilated conditions. It was 350 
estimated that active smokers delivered 6%–18% of the dose to passive smokers in an 351 
unventilated room, and this decreased with ventilation. At these estimated cannabis doses, 352 
volunteers reported some of the typical psychoactive effects of cannabis. However, the effects 353 
due to THC exposure remain difficult to interpret in the absence of a placebo session. 354 
 355 
Contamination 356 
In order to avoid direct contamination, it is recommended that blood specimens should be 357 
collected outside the contaminated place or room and that butterfly catheters are protected from 358 
cannabis smoke in serial blood sample collection. In the earliest studies, the elimination profiles 359 
in the plasma from the studies by Perez-Reyes et al. [21] and Mason et al. [54] were not 360 
considered in Figure 4a, due to possible contamination and the absence of controls or placebos. 361 
In these studies blood sampling only restricted the exposure period and collection occurred 362 
inside the exposure room so as to reach a steady-state THC level in volunteers (Supplementary 363 
Table 2). Unlike these two studies, Morland et al. [15] collected blood specimens after the 364 
exposure period and outside the exposure area in order to reduce the risk of contamination 365 
during blood sampling. 366 
 367 
Interpretation 368 
When interpreting blood results, it is important to consider certain factors other than the 369 
complete description of exposure parameters. Goullé et al. [29] interpreted the blood kinetics 370 
following inhalation by using a multiphase profile. High plasmatic concentrations of THC are 371 
reached within the first minutes of the inhalation phase. This is followed by an initially rapid 372 
decrease (distribution phase) and then a slower elimination, implying the use of a multi-373 
compartment pharmacokinetic (PK) model or alternative complex models. The multiphase 374 
absorption and elimination time-profile can be inferred from the broad range of early passive 375 
smoking studies presented by Cone et al. [5-7]. Volunteers stayed in a closed, unventilated 376 
room for six consecutive days and were exposed to 4 or 16 marijuana cigarettes (2.8% THC) for 377 
60 min each morning (Supplementary Table 2). Despite the daily repetition of exposure 378 
sessions, proof of THC accumulation in plasma remained inconclusive [7]. Nevertheless, the 379 
highest mean plasma levels (2.4 and 7.4 ng/mL for 4 and 16 cigarettes, respectively) were 380 
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indeed observed on the last day of exposure. The exposure conditions of this study were 381 
extreme and are unlikely to occur in daily practice (i.e., an unventilated room and 16 marijuana 382 
cigarettes smoked for 1 h each day for 6 consecutive days): volunteers had to wear goggles to 383 
tolerate the noxious smoky environment. 384 
Researchers have been trying to identify the criteria and potential markers able to distinguish 385 
active consumption from passive exposure from the very earliest studies on passive cannabis 386 
exposure [15; 21; 54]. In this perspective, Mason et al. [54] suggested comparing the 387 
concentrations of THC and THC-COOH in plasma; after active smoking, THC is present in low 388 
concentrations in the latter part of the elimination curve and THC-COOH levels always exceed 389 
those of THC: after passive exposure, THC-COOH concentrations are always lower than THC 390 
concentrations. This scenario can be observed by comparing Figures 4a and 4b. Consequently, 391 
threshold values for THC-COOH have been proposed for differentiating regular cannabis use 392 
from occasional smoking. Blood levels above 40 ng/mL of free THC-COOH strongly suggest 393 
regular consumption of cannabis [55; 56]. After passive exposure, Toennes et al. [51] and 394 
Röhrich et al. [22] reported THC-COOH concentrations in serum of 2 ng/mL at 1 h after 395 
exposure; it was lower than 1 ng/mL for THC. They thus suggested that THC and THC-COOH 396 
serum levels higher than 2 ng/mL would imply deliberate consumption. However, it remains 397 
unclear whether regular passive exposure over a long period can lead to higher cannabinoid 398 
levels. 399 
 400 
Overall, blood is an appropriate matrix to detect recent exposure and evaluate the effects of 401 
cannabis on behavior and performance. After passive exposure in extreme conditions, low and 402 
very low concentrations of THC and THC-COOH, respectively, should be observed (values 403 
should be insignificant 2 h after exposure). To avoid direct contamination of the matrix, sampling 404 
must be performed outside of the smoking area. 405 
 406 
Oral fluid 407 
Oral fluid (OF) is considered a suitable matrix for monitoring recent cannabinoid use or 408 
unintentional passive exposure [57]. It is commonly accepted that the presence of THC and 409 
THC-A (the plant precursor of THC) in OF is evidence of recent exposure to cannabis [17; 18]. 410 
The presence of THC-COOH molecules (free and conjugated) is generally considered as the 411 
best biomarker to detect active cannabis use as THC-COOH in OF is related to plasmatic 412 
concentrations and it is not present in smoke [58]. However, contrary to THC, THC-COOH 413 
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metabolite can be detected in a glucuronidated form and in very low concentration ranges 414 
(pg/mL), requesting more sensitive and up-to-date methods; consequently, most investigations 415 
are limited to THC as it is present in very high levels [14; 30; 57; 59; 60]. To increase the 416 
sensitivity of THC-COOH detection in OF, recent analytical methods have been developed 417 
either for including a preliminary step to hydrolyze THC-COOH-glucuronide or for determining 418 
THC-COOH and THC-COOH-glucuronide separately [59; 61; 62]. However, the presence of 419 
beta-glucuronidase enzymes in the OF could hydrolyze THC-COOH glucuronide and hamper 420 
the detection of glucuronide conjugates [57; 61]. Until now no study has demonstrated the 421 
presence of THC-COOH in OF following passive exposure to cannabis smoke [58], THC-COOH 422 
alone or in the free and conjugated forms should be monitored in OF to identify active cannabis 423 
smoking or in suspicion of active cannabis use. 424 
 425 
Analysis 426 
OF samples were analyzed by very sensitive, selective and specific two-dimensional gas-427 
chromatography high resolution mass spectrometry methods or by high resolution liquid 428 
chromatography interfaced with atmospheric pressure ionization coupled with tandem high 429 
resolution mass spectrometry (Table 2). These methods allow a direct analysis of OF without 430 
performing extraction previously [63]. Notwithstanding, a GC- or a target LC-MSMS method can 431 
be as sensitive as a high-resolution mass spectrometry (HR-MS); however, direct analysis of 432 
untreated oral fluid is not really recommended. 433 
 434 
Concentration ranges 435 
Five studies on the passive inhalation of cannabis smoke monitored THC concentrations in OF 436 
specimens. The Figure 5 represents the concentrations of THC time profile in OF of different 437 
studies during and following a passive exposure to cannabis. As illustrated in Figure 5, THC 438 
Cmax was observed until 20 min after exposure to cannabis smoke. THC concentrations were 439 
then seen to decrease rapidly until 60 min. Niedbala et al. [18] explained the high 440 
concentrations observed shortly after passive exposure to cannabis smoke by the fact that up to 441 
50% of the total THC content in a cannabis cigarette is released in sidestream smoke. 442 
Determining a reliable, accurate Cmax for cannabinoids using OF specimens is very difficult 443 
considering the sampling device’s potential for contamination and the rapid decrease in 444 
concentrations after passive exposure to cannabis smoke. Actually, the higher THC 445 
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concentrations observed in volunteers by Niedbala et al. [19] in their study I compared to their 446 
study II was probably due to device contamination (Supplementary Table 2). To limit 447 
contamination, Moore et al. [14] collected OF outside coffee shops in the Netherlands. However, 448 
variations in the number of smokers present inside the coffee shops during the 3-hour exposure 449 
period make the results difficult to interpret. This study only highlighted positive test results 450 
following passive exposure to cannabis smoke, but no conclusions could be made regarding 451 
kinetics or elimination after 3 h of exposure (Figure 5). 452 
 453 
Contamination 454 
As for blood sampling, to avoid direct contamination, OF specimens must be collected outside 455 
the contaminated place or room and sampling devices should be protected from cannabis 456 
smoke. Another element to consider as potential contamination is THC accumulation in the 457 
mucosa of the upper respiratory tract following active or passive smoking, even though 458 
cannabinoids are very poorly excreted in saliva [19; 30]. This contamination may last for 6 to 9 h 459 
and can be detected using an adequately sensitive test; however, positive tests are very rarely 460 
obtained more than 2 h after the last use [30; 64]. Furthermore, exposure to cannabis inhibits 461 
the formation of saliva, resulting in a dry mouth [24] and hampering the collection of OF just 462 
after cannabis exposure or smoking. 463 
 464 
Interpretation 465 
Reliable testing for THC in OF faces some analytical concerns and requires an efficient test 466 
system (i.e., collection device, screening procedure, or confirmation assay). Among the most 467 
important issues are: i) the potential environmental contamination of the collection devices, ii) 468 
the stability of THC and its absorption to the polystyrene surfaces of collection devices, iii) the 469 
variability in the design of collection devices, and iv) the potential for false-positive test results 470 
following passive exposure if low THC concentrations are measured [14; 17; 30; 57; 64]. 471 
To bypass these issues, other possible markers have been suggested for detecting active 472 
smoking and differentiating it from passive exposure: THC-COOH, THC-A, and other minor 473 
cannabinoids. Whether it is possible to detect THC-COOH in OF after long-term passive 474 
exposure to cannabis smoke has not yet been evaluated. Consequently, Cone et al. [9] 475 
suggested measuring THC-COOH in OF in order to differentiate active cannabis use from 476 
passive exposure as no THC-COOH concentrations were detected in non-smoker OF 477 
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specimens under their three session conditions. Moreover, THC-COOH has never been 478 
detected in either cannabis plants or the smoke from cannabis joints. Therefore, THC-COOH is 479 
the best-known marker of active cannabis consumption in OF, although the concentration cut-off 480 
selected (50 pg/mL) has a significant influence on how frequently it is detected compared to 481 
THC [65]. THC-A was also suggested as a marker because most THC/ cannabidiol-based 482 
medicines do not contain it. Its presence in OF is therefore probably due to its incomplete 483 
decarboxylation [66]. It could also be the result of direct contact between the plant material in 484 
the cannabis cigarette and the mouth. It should not be detectable in passive smokers. Lastly, 485 
Anizan et al. [67] proposed some minor cannabinoids, the cannabidiol (CBD), and the 486 
cannabinol (CBN) as markers of recent cannabis consumption. However, they were only 487 
detected when a single brand of cannabis cigarettes was tested, containing no tobacco and a 488 
specified proportion of THC and CBD. In addition, the presence of CBD could also be related to 489 
the therapeutic administration of a variety of medicinal cannabis [68]. THC, THC-COOH, and 490 
THC-A thus remain the main compounds that should be monitored in OF in order to distinguish 491 
active exposure from passive exposure to cannabis. A particular carefulness is nonetheless 492 
required if blood is present in OF (e.g., in case of bleeding gums) as it can noticeably increase 493 
cannabinoid concentrations [69; 70]. Consequently, determination of several cannabinoids may 494 
help to interpret concentration results in OF. 495 
 496 
The advantage of OF testing over urine testing is that the presence of THC in OF suggests 497 
recent exposure. A fraction of the THC retained in the oral cavity may be passively absorbed 498 
into the bloodstream through the mucosa, enhancing THC concentrations in blood [17]. 499 
Consequently, OF is probably not the most appropriate matrix to demonstrate or evaluate the 500 
extent of passive exposure to cannabis smoke. 501 
 502 
Hair 503 
Hair samples offer some advantages over other matrices: collection is non-invasive and less 504 
intrusive than urine or blood, and can be stored at room temperature. Sampling limitations 505 
include baldness or short hair [25]. The presence of cannabinoids in hair, especially THC, 506 
provides information on repeated or chronic exposure [25; 64]. 507 
 508 
Analysis 509 
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To quantify cannabinoids in hair, analytical methods require to detect femto- to picogram 510 
residue ranges per milligram of hair [30]. From the end of 1990’s, the main analytical methods 511 
used to analyze THC in hair was via GC-MS. Recently, THC-A can also be measured in hair, 512 
and as for THC-COOH a negative ion chemical ionization mass spectrometry, GC-NCI–MS or 513 
GC-NCI–MS/MS is needed [4]. A new approach has also been developed by Duvivier et al. [71] 514 
and consists of a longitudinal scanning of THC in hair using direct analysis in real time (DART) 515 
ambient ionization orbitrap MS. This method allows to perform a pre-screening test of THC in 516 
hair without sample preparation. 517 
 518 
Concentration ranges 519 
THC is the most common compound measured in hair, followed by CBD and CBN, and THC-520 
COOH [4; 30]. THC and THC-COOH have very low incorporation rates into hair [72]. THC’s 521 
presence may be explained by its weak bond to melanin, whereas THC-COOH’s absence may 522 
be due to the acidic nature of hair [4; 25]. 523 
In the study by Moosmann et al. [73], the highest concentrations in hair for THC, THC-A, and 524 
CBN were observed at the end of the passive exposure period, i.e., after an exposure of one 525 
joint every weekday for three weeks (17.3 pg/mg for THC-A, 803 pg/mg for THC, and 307 526 
pg/mg for CBN; Table 2). THC-COOH in urine was measured twice a week during the exposure 527 
period in order to control abstinence in volunteers. Hair analyses for THC-A and THC-COOH 528 
could be considered as useful complementary procedures for monitoring active and passive 529 
exposure using other matrices. The only exposure to cannabis that the detection of plant 530 
cannabinoids in hair (THC-A, CBD, THC-V) excludes is a single oral administration of a 531 
therapeutic dose of synthetic THC (dronabinol). THCV (in hair) and its metabolite THCV-COOH 532 
(in urine) could be useful markers to differentiate dronabinol intake from exposure to cannabis 533 
smoke [74]. 534 
 535 
Contamination 536 
With regard to exposure to passive smoke, environmental contamination may cause 537 
misinterpretations and false-positive test results [75]. Contamination is mainly due to cannabis 538 
smoke, to direct contact with contaminated surfaces, without ruling out the possibility of an 539 
exposure to urine aerosols present in contaminated public lavatories and public areas (Figure 540 
1). To reduce this potential for contamination and prevent false-positive results, it is advisable to 541 
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perform extensive hair washing procedures before analyses, measure both THC and THC-542 
COOH, select appropriate cut-offs, and analyze the wash-off residue [25; 76; 77]. Because 543 
marijuana smoke does not contain THC-COOH but THC, the detection of even trace 544 
concentrations of THC-COOH might well indicate active use, whereas its absence does not 545 
preclude cannabis consumption at all [4; 25; 77]. Some recent studies have also recommended 546 
measuring THC-A in hair, in order to distinguish passive exposure from active cannabis use [4; 547 
73; 78]. THC-A in hair originates exclusively from external contamination, mainly by direct 548 
transfer after manipulation of cannabis plant material, or through smoke condensing on the hair 549 
shaft. In cannabis smoke, only small amounts of THC-A are present resulting from incomplete 550 
decarboxylation; this suggests a more important source of contamination than the deposition of 551 
sidestream smoke. Consequently, THC-A is monitored as a biomarker of environmental 552 
contamination. 553 
 554 
Interpretation 555 
Interpreting an analysis of the hair matrix is also quite complex. At least six mechanisms are 556 
thought to be involved in the incorporation of cannabinoids into the hair’s shaft and root. For the 557 
hair shaft, cannabinoids may be incorporated from a) environmental exposure to cannabis 558 
smoke, b) direct contact with a contaminated object or body part, c) exposure to sweat or d) 559 
sebum, or e) diffusion from the skin. For the hair’s root, cannabinoids could be incorporated 560 
from the bloodstream during hair development [25; 30; 64]. Mechanisms a) and b) are related to 561 
external contamination, whereas the other mechanisms require active biological processes. If 562 
one supposes that cannabinoids are almost exclusively incorporated through the bloodstream, a 563 
sequential analysis of hair segments would allow assessing past periods of drug consumption or 564 
abstinence. However, it is currently assumed that the THC (like all the other plant cannabinoids 565 
and CBN) measured in hair is almost exclusively the result of external contamination and not 566 
from incorporation through the bloodstream. This has been evidenced by the distribution of THC 567 
along the entire hair shaft after passive exposure to marijuana smoke, despite intensive hair 568 
washing. Therefore, to retrospectively assess cannabis use, a segmental hair analysis is not 569 
scientifically founded. Washing procedures are equally ineffective for removing other hair 570 
contaminants, and similar observations have been noticed for THC metabolites. Because THC-571 
COOH concentrations decreased from the proximal to the distal segments of the hair shaft, 572 
Auwärter et al. [4] suggested that metabolites are transferred to it via sebum by diffusion along 573 
and inside the shaft. Moreover, results from segmental analyses evidenced barely any 574 
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correlation between self-reported past periods of consumption and changes in THC-COOH 575 
levels in correspondingly aged hair segments [79]. 576 
Other important elements to consider in the interpretation of results are hair sampling sites and 577 
the hair’s condition. In their study involving the chronic marijuana smoke exposure of three 578 
volunteers using a breathing apparatus to avoid smoke inhalation, Moosmann et al. [73] 579 
observed that the degree of contamination depended on hair length and on the sampling site on 580 
the skull. The posterior vertex (the back of the top) was the most contaminated area of the 581 
head. This is also the sampling site that several scientific societies recommend for routine 582 
forensic investigations. The study also noted that short hairs were less contaminated than long 583 
hairs due to the more effective removal of hair sebum from the skin surface in daily washing; 584 
hair sebum stores and transfers cannabinoids along the hair shaft [73]. Another explanation 585 
could be that short hair is “younger” and its external cuticle is less porous and more impervious 586 
than longer, older distal hair. The diffusion of external contamination into the cortex and medulla 587 
of young hair is far less important. Likewise, physically or chemically damaged hairs are more 588 
affected by external contamination than healthy hairs. They thus present a higher risk of testing 589 
positive, even after a single exposure to cannabis smoke. The detection of damaged hair, as 590 
suggested by Hill et al. [80], is thus an opportunity to avoid a cosmetic bias. 591 
In summary, cannabinoid measurements in hair remain useful as a complementary matrix. A 592 
lack of cannabinoid detection at the recommended cut-off levels suggests abstinence or very 593 
occasional consumption. If THC is detected in hair, then it undoubtedly originates from 594 
contamination, however, that does not mean that this contamination was not initiated by the 595 
individual tested when smoking cannabis or preparing marijuana cigarettes. Contamination by 596 
nearby smokers is also possible, especially in a heavily contaminated environment. To confirm 597 
an external contamination, THC-A may be quantified. An extensive washing procedure should 598 
also be performed before hair analysis and wash residues should be analyzed when necessary. 599 
 600 
Sweat and sebum 601 
As with OF and hair, sweat is a non-invasive means of collecting biological specimens. Based 602 
on drug pharmacokinetics, sweat has been reported to be a suitable alternative matrix for 603 
monitoring recent drug use or external contamination. Its fat properties also allows the transfer 604 
of cannabinoids to the hair shaft [30]. 605 
 606 
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Analysis 607 
Sweat can be sampled by dedicated sweat patches (e.g., Pharmchek® absorption pads, Fort 608 
Worth, Texas, USA); however, depending on the sampling site, sweat is generally mixed with 609 
sebum, forming an emulsion [81]. This emulsion is sampled using special cotton swabs; sebum 610 
is more easily collected using special lipid-sensitive tapes (e.g., Sebutape®, Cuderm Corp, 611 
Dallas, USA or Sebufix@, C+K Electronic, Cologne, Germany). However, only the drug fraction 612 
not bonded to proteins can diffuse from plasma to sweat through lipid membranes [81]. 613 
Nonetheless, the drug fraction excreted in sweat by passive diffusion is sufficient to be analyzed 614 
using standard mass spectrometry methods. It remains that patch analysis requires sensitive 615 
analytical methods (in the ng/patch range). 616 
 617 
Concentration ranges, contamination, and interpretation 618 
It appears that only THC can be measured in sweat; THC-COOH being never detected, or in 619 
extremely low concentrations [82]. Because of its neutral properties, THC diffusion is suspected 620 
to be slow [81]. Therefore, THC is monitored by using a patch sampling method from a specific 621 
time point in order to detect recent cannabis use. The interpretation of results is complicated by 622 
a potential re-absorption of THC by the skin, the adsorption of THC onto the patch-collection 623 
device, and environmental contamination [30; 81]. No THC should be detected in sweat in 624 
cases of passive exposure, as no THC was measured in recreational cannabis users, who 625 
should have similar or higher exposure levels to cannabis than passive smokers [81]. Sebum, 626 
however, could be a vector of THC-COOH by transferring it from bodily stores and fluids to hair 627 
shafts [83]. 628 
 629 
Analytical limitations 630 
In addition to a potential contamination, analytical issues may also be influential, and some 631 
analytical methods produce artifacts. Typical examples are the hydrolysis of conjugates, the 632 
conversion of THC-A into THC (under alkaline conditions or upon heating), the isomerization of 633 
delta-9-THC into delta-8-THC (under acid conditions), or the possible conversion of CBD into 634 
THC (under acid conditions). A further problem is that results are not always reported as levels 635 
of free cannabinoids or as total cannabinoids (the sum of free and conjugated molecules), nor 636 
are levels normalized to the creatinine concentration for urine samples. All these issues 637 
complicate the interpretation of results and make comparisons impossible. 638 
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 639 
Conclusion 640 
From the studies identified on passive exposure to cannabis of non-user subjects in controlled 641 
conditions, specific biomarkers of passive cannabis exposure were identified in urine, blood, 642 
oral fluid, hair, and sebum. It results that urine is an appropriate matrix to monitor passive 643 
exposure, especially after normalization to creatinine levels. Important concentrations of THC-644 
COOH can be measured; however, concentrations exceeding the usual thresholds of positivity 645 
require very extreme environmental conditions that cannot be ignored. Likewise, low blood 646 
concentrations of THC and THC-COOH could be determined for a few hours following acute 647 
exposure to heavy cannabis smoke. Measuring THC-COOH in blood is also a good alternative 648 
for appraising passive exposure as it is detectable for a much longer time than THC and it 649 
accumulates to high levels during chronic use. THC is detected in oral fluid after active 650 
consumption or passive exposure. However, THC-COOH which is found only after voluntary 651 
consumption can be considered as a reliable marker of active use. If the skin and the sebum are 652 
easily contaminated by cannabis smoke, the skin layer limits the passage of cannabinoids into 653 
the bloodstream. However, cannabinoids can be incorporated from sebum into the hair shaft by 654 
diffusion. The presence of THC and THC-A in hair indicates that the subjects live or work in an 655 
environment contaminated with cannabis. The detection of THC-COOH argues for regular 656 
active use of cannabis. In contrast, a long period of abstinence can be strongly suspected if no 657 
cannabinoids are detected in the hair shaft. 658 
From a forensic outlook, in order to demonstrate conclusively that the cannabinoids measured 659 
from different parts of the body are the result of active consumption, the expert should be able 660 
to positively exclude different sources of potential contamination, such as: 661 
• Self and cross-contamination from cannabis users: heavily contaminated hands and 662 
fingers, contaminated surfaces or cannabis smoke can contaminate a non-smoker’s 663 
body as a result of poor personal hygiene and their environment; 664 
• Extreme exposure to cannabis smoke: this may result in subjective and pharmacological 665 
effects on physiology, behavior, cognitive capabilities, and psychomotor performances, 666 
and these effects may sometimes be similar to those experienced by active smokers, 667 
especially when the potency of cannabis is high; 668 
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• Secondhand smoke contamination: this should also be considered, especially in cases 669 
of extreme exposure conditions. Thirdhand and secondhand contaminations are usually 670 
difficult to discern and may be combined and cumulated. 671 
 672 
As a concluding remark, the experts should clearly inform persons who have to demonstrate 673 
prolonged abstinence from cannabis to avoid heavily smoky and unventilated areas. Moreover, 674 
such persons must not handle or come into contact with objects and surfaces containing or 675 
contaminated with cannabis material. 676 
  677 
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Fig 1. Creative Commons License Deed 694 
Figure 1 is adapted from a figure in the Moosmann et al. [84] article entitled “Finding 695 
cannabinoids in hair does not prove cannabis consumption”. The original version is licensed 696 
under a Creative Commons Attribution 4.0 International License, a copy of which can be found 697 
at http://creativecommons.org/licenses/by/4.0/. The figure was modified as follows, after 698 
discussion with the original authors. An additional arrow indicates possible contamination of the 699 
hair by urinary THC-COOH. The transfer of THC is described differently, with references to 700 
secondhand and thirdhand smoke, and to mainstream and sidestream smoke. Secondhand 701 
cannabis smoke is a mixture of the smoke from a smoldering marijuana cigarette (sidestream 702 
smoke) and the smoke exhaled by a smoker (mainstream smoke). The cannabis smoke 703 
condensate left on a variety of indoor surfaces, which is also a potential source of environmental 704 
contamination, is known as thirdhand smoke. 705 
 706 
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Table 1 Cut-offs proposed by different scholarly societies according to biological matrices and analytes 
 
Society Biological matrix Initial test analyte 
(immunoassay) 
Initial test cut-off 
concentration 
Confirmatory test 
analyte 
Confirmatory test 
cut-off 
concentration 
SAMHSA 2008a,b urine Marijuana 
metabolites 
50 ng/mL THC-COOH total 15 ng/mL 
GTFChc urine   THC-COOH total 10 ng/mL 
EWDTS 2015d urine Marijuana 
metabolites 
50 ng/mL THC-COOH 15 ng/mL 
GTFChc serum/plasma   THC free 1 ng/mL 
GTFChc serum/plasma   THC-COOH free 10 ng/mL 
SFTAe whole blood   THC 0.5 ng/mL 
SFTAe whole blood   THC-COOH 2.0 ng/mL 
GTFChc hair   THC 0.02 ng/mg 
SoHTf hair THC 0.1 ng/mg THC 0.1 ng/mg 
SoHTf hair   THC-COOH 0.2 pg/mg 
EWDTS 2015d hair THC 0.05 ng/mg THC 0.05 ng/mg 
EWDTS 2015d hair   THC-COOH 0.2 pg/mg 
SAMHSA 2004g hair Marijuana 
metabolites 
1 pg/mg THC-COOH 0.05 pg/mg 
SAMHSA 2004g oral fluid/saliva THC 4 ng/mL THC 2 ng/mL 
SAMHSA 2015 
(proposal)h 
oral fluid/saliva THC 2-3 ng/mL THC 1 ng/mL 
SAMHSA 2015 
(proposal)h 
oral fluid/saliva   THC-COOH 50 pg/mL 
EWDTS 2015d oral fluid/saliva THC 10 ng/mL THC 2 ng/mL 
SAMHSA 2004g sweat patch Marijuana 
metabolites 
4 ng/patch THC 1 ng/patch 
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a Substance Abuse and Mental Health Services Administration (SAMHSA) (2008) Mandatory guidelines for Federal 
workplace drug testing programs. Federal Register, 73, No. 228. pp. 71,858–71,907. Rockville, MD: Substance Abuse 
and Mental Health Services Administration. Available at: https://www.gpo.gov/fdsys/pkg/FR-2008-11-25/pdf/E8-26726.pdf. 
Accessed December 18, 2015. 
b Substance Abuse and Mental Health Services Administration (SAMHSA) (2015) Notice of proposed mandatory 
guidelines for Federal workplace drug testing programs – Urine. Federal Register, 80, No. 94. pp. 28,101–28,151. 
Rockville, MD: Substance 
Abuse and Mental Health Services Administration. Available at: https://www.gpo.gov/fdsys/pkg/FR-2015-05-15/pdf/2015-
11524.pdf. Accessed December 18, 2015. 
c GTFCh: Gesellschaft für Toxikologische und Forensische Chemie. Anhang A zur Richtlinie zur Qualitätssicherung bei 
forensisch-toxikologischen Untersuchungen. Qualitätsanforderungen an die Bestimmung spezieller Analyten aus 
biologischen Matrices mit Tabellenanhang (aktuelle Vorgaben zu Bestimmungsgrenzen). 01.06.2009. Toxichem Krimtech 
(2009) 76 (3): 177-184. 
d EWDTS: European Laboratory Guidelines for Legally Defensible Workplace Drug Testing (2015). Available at: 
http://www.ewdts.org/ewdts-guidelines.html. Accessed December 18, 2015. 
e SFTA: Société Française de Toxicologie Analytique. Consensus Cannabis, 2013, June 14th. Available at: 
http://www.sfta.org/img/uploads/2015/07/Consensus_cannabis_2013.pdf. Accessed December 18, 2015. 
f SoHT: Society of Hair Testing. Consensus on hair testing, 2003, October 7th. Available at: 
http://www.soht.org/images/pdf/Consensus_on_Hair_Analysis.pdf. Accessed December 18, 2015. 
g Substance Abuse and Mental Health Services Administration (SAMHSA) (2004) Mandatory guidelines and proposed 
revisions to mandatory guidelines for Federal workplace drug testing programs. Federal Register, 69, No. 71. pp. 19,675–
31 
19,732. Rockville, MD: Substance Abuse and Mental Health Services Administration. Available at: 
https://www.gpo.gov/fdsys/pkg/FR-2004-04-13/html/04-7984.htm. Accessed December 18, 2015. 
h Substance Abuse and Mental Health Services Administration (SAMHSA) (2015) Notice of proposed mandatory 
guidelines for Federal workplace drug testing programs – Oral fluid. Federal Register, 80, No. 94. pp. 28,054–28,101. 
Rockville, MD: Substance 
Abuse and Mental Health Services Administration. Available at: https://www.gpo.gov/fdsys/pkg/FR-2015-05-15/pdf/2015-
11523.pdf 
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Table 2 Summary of the analytical methods used, the cut-offs, and the maximum cannabinoid body fluid 
concentrations reported in studies on the passive exposure to cannabis 
Reference Matrix Analytes Analytical 
methoda 
LOD of 
analytical 
method 
(ng/mL) 
Cut-off 
(ng/mL) 
Exposure 
time 
(min) 
THC dose 
(mg) 
Cmax (ng/mL) 
(time after 
exposure)b 
[21] Study I Urine Cannabinoids EMIT n.a. 20 60 46 < cut-off 
  Study II Urine Cannabinoids EMIT n.a. 20  52 < cut-off 
  Study III Urine Cannabinoids EMIT n.a. 20  105 < cut-off 
[13] Plasma THC RIA n.a. 3 60 105 2.2 (5 min) 
  THC GC/MS 0.2 n.a.   4 (5 min) 
  11-OH-THC GC/MS 0.5 n.a.   Negative 
  THC-COOH GC/MS 0.1 n.a.   < 0.1 
[11] Urine THC-COOH + its ester glucuronide RIA 
0.32 ± 0.23 
(mean ± SD) 2 180 
103 4.7 (90 min) 
 Plasma THC-COOH + its ester glucuronide RIA 
1.8 ± 2.5 
(mean ± SD) 2  
 0 
[15] Study I Urine Cannabinoids EMIT n.a. 20 30 90 Negative 
  Cannabinoids RIA n.a. 13   NA 
 Blood Cannabinoids RIA n.a. 13   < cut-off 
  THC GC/MS 0.5 0.5   1.3 – 6.3 (immediately) 
[15] Study II Urine Cannabinoids EMIT n.a. 20 30 90 < cut-off 
  Cannabinoids RIA n.a. 13   21 (immediately) 
 Blood Cannabinoids RIA n.a. 13   20 (immediately) 
  THC GC/MS 0.5 0.5   1.3 – 6.3 (immediately 
[5-7] 
Urine Cannabinoids EMIT n.a. 20 
60 (6 
consecutive 
days) 
393.4 
(average 
weight of 
cigarettes: 
877±20 mg) 
Positive urines after 1st 
exposure session for 6 
subjects (n = 16 cigs) 
 
 Cannabinoids RIA 5 10  
≈75 days 2–6 (n = 16 
cigs) 
≈14.1 days 2–6 (n = 4 
cigs) 
 
 THC-COOH GC/MS 2 5  
 30 at day 4 (n = 16 
cigs) 
almost 0 (n = 4 cigs) 
 
Plasma THC RIA 1.5 2.5  
 7.3 at day8 (n = 16 
cigs) 
2.5 at day6 (n = 4 cigs) 
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Reference Matrix Analytes Analytical 
methoda 
LOD of 
analytical 
method 
(ng/mL) 
Cut-off 
(ng/mL) 
Exposure 
time 
(min) 
THC dose 
(mg) 
Cmax (ng/mL) 
(time after 
exposure)b 
[16] Urine Cannabinoids RIA n.a. 12 60 108 < 6 
[20] Study I Urine THC EMIT n.a. 20 60 45 8.5 (120 min) 
  THC ADx n.a. 25   5.7 (44 h) 
  Study II Urine THC EMIT n.a. 20 30 30 9.6 (7h) 
  THC ADx n.a. 25   21.3 (7 h) 
[17] Urine THC-COOH EIA 3 50 240 n.a. 3.2 (24 h) 
  THC-COOH GC/MS/MS 5 15   Negative 
 Oral fluid THC EIA 0.5 1   Positive (60 min)  THC GC/MS/MS 0.2l 0.5   Negative 
[18] Urine THC-COOH EIA n.a. 50 240 n.a. Negative 
  THC-COOH GC/MS/MS 1 1   0.9 (5 min) 
 Oral fluid THC EIA n.a. 3   Positive (20 min after start of exposure) 
 THC GC/MS/MS 0.3 0.75   13.4 (20 min after start of exposure) 
[19] Study I Urine THC-COOH EIA n.a. 50 60 158 Negative 
  THC-COOH GC/MS/MS 1 1   8.4 (6h) 
 Oral fluid THC EIA n.a. 3   Positive (15 min) 
 THC GC/MS/MS 0.3 0.75   5.3 (immediately) 
  Study II Urine THC-COOH EIA n.a. 50 60 333 Negative 
  THC-COOH GC/MS/MS 1 1   8.9 (6h) 
 Oral fluid THC EIA n.a. 3   Negative 
  THC GC/MS/MS 0.3 0.75   1 (90 min) 
[22] Urine THC-COOH ELISA n.a. 0.6 180 n.a. 0.8 (30 min) 
  Cannabinoids EIA 1.3 25   9.8 (3h) 
  THC-COOH GC/MS 0.4 0.6   2.3 (11h) 
 Hydrolyzed 
urine 
THC-COOH 
 GC/MS 0.7 1  
 3.8 (11h) 
 Serum Cannabinoids ELISA 1 3   3 (30 min) 
  THC GC/MS 0.1 0.5   0.5 (1.5 h after the start of exposure) 
[23] Urine Cannabinoids EIA n.a 25 180 8 g of 
hashish and 
marijuana 
were burnt 
Negative 
  THC-COOH GC/MS 1 8  3.6 (3h) 
 Serum Cannabinoids EIA n.a 3  2/8 volunteers positive (30 min) 
  THC GC/MS 0.1 1  Negative 
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Reference Matrix Analytes Analytical 
methoda 
LOD of 
analytical 
method 
(ng/mL) 
Cut-off 
(ng/mL) 
Exposure 
time 
(min) 
THC dose 
(mg) 
Cmax (ng/mL) 
(time after 
exposure)b 
  11-OH-THC GC/MS 0.1 1   Negative 
  THC-COOH GC/MS 1 8   ≈ LOD (0.5-3 h) 
[14] Location 1 Oral fluid THC ELISA 2 4 180 n.a. Positive over the 20 min to 3h exposure 
  THC GC/MS 0.5 0.5   4.3 (2h after the start of exposure) 
  Cannabinol GC/MS 0.5 0.5   0.7 (2h after the start of exposure) 
  Cannabidiol GC/MS 1 1   Negative 
  THC-COOH Two-dimensional GC-GC/MS 0.002 > 0.002  
 Negative 
 Location 2 Oral fluid THC ELISA 2 4 180 n.a. Positive (immediately) 
  THC GC/MS 0.5 0.5   7.5 (immediately) 
  Cannabinol GC/MS 0.5 0.5   0.9 (immediately) 
  Cannabidiol GC/MS 1 1   Negative 
  THC-COOH Two-dimensional GC-GC/MS 0.002 > 0.002  
 Negative 
[8; 9] Session I Urine Cannabinoids EMIT n.a. 50 60 5.3% Negative 
  THC EMIT n.a. 20   85.6 (4-6h) 
  THC-COOH GC/MS 0.75 15   22.4 (4-6h) 
 Whole 
blood THC LC/MS/MS 0.1 0.5  
 1.4 (15 min) 
  THC-COOH (free) LC/MS/MS 0.1 0.5   1.2 (15 min) 
  11-OH-THC LC/MS/MS 0.1 0.5   Negative 
 Oral Fluid Cannabinoids ELISA 2 4   Positive (15 min) 
  THC LC/MS/MS 0.1 1   34 (15 min) 
  THC-COOH (total) LC/MS/MS 0.02 0.02  
 Negative 
 Session II Urine Cannabinoids EMIT n.a. 50 60 11.3% Negative 
  THC EMIT n.a. 20   140 (4h) 
  THC-COOH GC/MS 0.75 15   33.3 (4h) 
 Whole 
blood THC LC/MS/MS 0.1 0.5  
 3.1 (15 min) 
  THC-COOH (free) LC/MS/MS 0.1 0.5   2.5 (15 min) 
  11-OH-THC LC/MS/MS 0.1 0.5   Negative 
 Oral Fluid Cannabinoids ELISA 2 4   Positive (15 min) 
35 
Reference Matrix Analytes Analytical 
methoda 
LOD of 
analytical 
method 
(ng/mL) 
Cut-off 
(ng/mL) 
Exposure 
time 
(min) 
THC dose 
(mg) 
Cmax (ng/mL) 
(time after 
exposure)b 
  THC LC/MS/MS 0.1 1   81.5 (15 min) 
  THC-COOH (total) LC/MS/MS 0.02 0.02  
 Negative 
 Session III Urine Cannabinoids EMIT n.a. 50 60 11.3% Negative 
  THC EMIT n.a. 20   55.2 (4-6h) 
  THC-COOH GC/MS 0.75 15   8.61 (4h) 
 Whole 
blood THC LC/MS/MS 0.1 0.5  
 0.5 (15 min) 
  THC-COOH (free) LC/MS/MS 0.1 0.5   0.2 (15 min) 
  11-OH-THC LC/MS/MS 0.1 0.5   Negative 
 Oral Fluid Cannabinoids ELISA 2 4   Positive (15 min) 
  THC LC/MS/MS 0.1 1   16.9 (15 min) 
  THC-COOH (total) LC/MS/MS 0.02 0.02  
 Negative 
[73] Urine THC-COOH EMIT n.a. 10 
15-20 min 
(one joint) 
every 
weekday for 
3 weeks 
500 mg of 
marijuana 
containing 
9.2% THC 
Negative 
 Hair THC-A LC/MS/MS 2.5 pg/mg 2.5 pg/mg 17.3 pg/mg (end of exposure period) 
  THC LC/MS/MS 20 pg/mg 20 pg/mg 803 pg/mg (end of exposure period) 
  Cannabinol LC/MS/MS 20 pg/mg 20 pg/mg 307 pg/mg (end of exposure period) 
 
EIA: Cannabinoids Intercept MICRO-PLATE Enzyme Immunoassay; ELISA: Enzyme linked immunosorbent assay; EMIT: Enzyme 
multiplied immunoassay technique; GC/MS: Gas chromatography–mass spectrometry; GC/MS/MS: Gas chromatography–tandem 
mass spectrometry; LC/MS/MS: liquid chromatography coupled with tandem mass spectrometry; n.a.: non available; RIA: 
Radioimmunoassay;  
 
a Analytical methods reported to be used in the referent study on passive exposure to cannabis. 
b The maximal concentration obtained in calculating a mean between the non-smoker values at a specific time. 
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Figure captions 1 
 2 
Fig. 1 Potential external cross-contamination from cannabis use and incorporation pathways of 3 
cannabinoids into human hair. Incorporation of Δ9-tetrahydrocannabinolic acid A (THCA-A), Δ9-4 
tetrahydrocannabinol (THC), and its metabolite, 11-nor-9-carboxy-THC (THC-COOH), into 5 
human hair can occur in the hair’s root via the bloodstream, by diffusion from sweat or sebum 6 
into the hair shaft, or by external contamination (e.g., contaminated fingers or sidestream 7 
smoke). The main metabolic pathway for THC and the molecular structures of its analytes are 8 
also given. Reprinted and adapted with the permission by “Nature Publishing Group” and 9 
“Creative Commons”, “Finding cannabinoids in hair does not prove cannabis consumption, 10 
2015, p. 2, Figure 1” [84]. 11 
 12 
Fig. 2 Bioavailability and elimination of cannabinoids in different matrices following passive 13 
exposure to cannabis smoke. Cannabinoids in bold type denote markers considered suitable for 14 
differentiating passive from active exposure. Reprinted and adapted with permission by 15 
“Science Direct” and “Elsevier Science”, “Mise en evidence des cannabinoïdes : quel milieu 16 
biologique ? [Which biological matrix for cannabis testing?], 2006, p. 186, Figure 5” [64]. 17 
 18 
Fig. 3 THC-COOH concentration time profiles in urine reported in several studies on passive 19 
exposure to cannabis smoke. Profiles are adjusted for creatinine concentrations. Each study is 20 
identified by a differently-shaped dot, with different colors denoting different sessions. 21 
 22 
Fig. 4 Concentration time profiles of a) THC in plasma or b) THC-COOH in serum and whole 23 
blood reported in several studies on passive exposure to cannabis smoke. Each study is 24 
identified by a differently-shaped dot, with different colors denoting different sessions. 25 
 26 
Fig. 5 THC concentration time profiles in oral fluid reported in several studies on passive 27 
exposure to cannabis smoke. Each study is identified by a differently-shaped dot, with different 28 
colors denoting different sessions. 29 
 30 
 31 
37 

 
 
 
 
 
 
Bioavailability 
18-25% 
Inhalation ORAL FLUID 
 
 THC 
 THC-A 
Ingestion ORAL FLUID 
 
 THC 
 THC-A 
 FECES 
 
THC-COOH 
11-OH-THC 
THC < 5% 
THC-A? 
60%–80% 20%−35% 
 URINE 
 
THC-COOH glucuronide 
THC (traces) 
THC-A 
THC > THC-COOH (traces) 
THC-A 
THC > THC-COOH (traces) 
THC-A 
Inhalation HAIR 
 
 THC > THC-COOH (traces) 
 THC-A 
Inhalation BLOOD 
 
THC > THC-COOH 
11-OH-THC 
THC-A 
Ingestion BLOOD 
 
THC-COOH 
THC ≈ 11-OH-THC 
THC-A 
Bioavailability 
Smoke: 6%−25% 
Cross-contamination: 
may be important 



PUBMED 
 
 
132 
references 
WOS 
 
 
362 
references 
MEDLINE 
OVID SP 
 
152 
references 
EMBASE 
 
 
243 
references 
COCHRANE 
LIBRARY 
 
25 
references 
CINAHL 
 
 
25 
references 
SCHOLAR 
 
 
12 
references 
 
 
 
958 references 
 
 
466 duplicates 
 
492 article titles identified by search 
criteria 
 
394 titles not relevant 
 
98 abstracts read 
 
64 abstract not relevant 
 
34 full texts obtained 
 
13 articles not relevant 
 
21 articles reviewed 
 
 
Non-relevant articles by title: 
Articles or studies on animals, relative to infertility, preconception, pregnancy, infants, children, 
teen-agers, nicotine dependence, effects of cannabis use, health effects, polymorphism, human 
milk. 
Non-relevant articles by abstract: 
No human biomonitoring sampling, quantification methods only, no passive volunteers or 
participants, opinion. 
Non-relevant articles by full texts: 
No data on passive exposure (human biological matrices), no placebo volunteers (only 
smokers), no relevant data. 
 
 
Table 1 Summary of the analytical methods used and the cannabinoid body fluid concentrations reported in studies on the passive 
inhalation of cannabis 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
Perez-Reyes et al. (1983) 
Urine (Study I) EMIT 20 Cannabinoids All urines collected separately 
for 24 h after exposure 
26 urine samples 24 h after 
exposure 
 Urinary drug levels were below 
the cut-off 
Urine (Study II) EMIT 20 Cannabinoids All urines collected separately 
for 24 h after exposure 
23 urine samples 24 h after 
exposure 
 One urine was above the cut-off 
at 6 h after exposure 
Urine (Study III) 
 
 
Plasma (Study III) 
EMIT 
 
 
RIA 
20 
 
 
NA 
Cannabinoids 
 
 
THC 
All urines collected separately  
for 3 consecutive days 
 
Blood collected from one 
subject at different intervals 
for 1 h after exposure 
27 urine samples 
 
 
11 blood samples 
72 h after 
exposure 
 
1 h after the 2nd 
exposure day 
 
 
 
1.9 ng/ml 
One urine slightly above the cut-
off at 5 h after 3rd exposure day 
 
2.2 ng/ml at 5 min after exposure 
Mason et al. (1983) 
Plasma RIA 
 
 
GC/MS 
3 
 
 
NA 
THC 
 
 
THC 
 
11-OH-THC 
 
THC-COOH 
Blood samples obtained at 
frequent intervals from 
beginning of exposure to 1 h 
after exposure 
24 blood samples 
 
 
24 blood samples 1 h after 
exposure 
1.9 ng/ml 
 
 
3 ng/ml 
 
NA 
 
0.5 ng/ml 
2–2.2 ng/ml at 5 min after 
exposure 
 
4 ng/ml at 5 min after exposure 
 
Not detected 
 
< 0.5 ng/ml 
Law et al. (1984) 
Urine 
 
 
Plasma 
RIA 
 
 
RIA 
2 
 
 
NA 
11-OH-THC- 
and its ester 
glucuronide 
At 0, 1, 2, 3, 6 h 
 
 
At 0, 0.5, 1, 2 and 4 h 
20 urine samples 
 
 
20 blood samples 
6 h after start of 
exposure 
 
4 h after start of 
exposure 
4.2 ng/ml at 6 h after 
start of exposure 
 
NA 
4.7 ng/ml at 4.5 h after start of 
exposure 
 
0 ng/ml 
Morland et al. (1985) 
Urine (Study I)b 
 
 
 
Blood (Study I)b 
EMIT 
 
RIA 
 
RIA 
 
 
20 
 
13 
 
13 
 
 
Cannabinoids 
 
Cannabinoids 
 
Cannabinoids 
 
 
Before exposure, 0 to 4h, 4 to 
24 h, and days 2, 3, 4, and 5 
 
 
Before exposure, immediately 
after exposure (0.5 h) and 2 h 
later (2.5 h) 
11 urine samples 
 
 
 
6 blood samples 
Day 5 morning 
 
 
 
2.5 h after start 
of exposure 
Negative 
 
NA 
 
0 ng/ml 
 
 
Negative 
 
NA 
 
One sample was at the cut-off at 
30 min. 
 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
GC/MS 0.5 THC 0 ng/ml 1.2 ng/ml at 30 min after start of 
exposure 
Urine (Study II)c 
 
 
 
Blood (Study II)c 
EMIT 
 
RIA 
 
RIA 
 
 
GC/MS 
20 
 
13 
 
13 
 
 
0.5 
Cannabinoids 
 
Cannabinoids 
 
Cannabinoids 
 
 
THC 
Before exposure, 0 to 4h, 4 to 
24h, and days 2, 3, 4, and 5 
 
 
Before exposure, immediately 
after exposure (0.5 h) and 2 h 
later (2.5 h) 
20 urine samples 
 
 
 
9 blood samples 
Day 5 morning  
 
 
 
2.5 h after start 
of exposure 
Negative 
 
< cut-off 
 
18 ng/ml 
 
 
0 ng/ml 
One sample positive at 4–24 h 
 
22 ng/ml at Day 2 morning 
 
26 ng/ml at 30 min after start of 
exposure 
 
5.2 ng/ml at 30 min after start of 
exposure 
Cone and Johnson (1986); Cone et al. (1987a); Cone et al. (1987b) 
Urine 
 
 
 
 
 
 
 
 
 
 
 
Plasma (venous 
blood) 
EMIT 
 
 
 
 
RIA 
 
 
 
GC/MS 
 
 
RIA 
20 and 
75 
 
 
 
10 
 
 
 
5 
 
 
2.5 
Cannabinoids 
 
 
 
 
Cannabinoids 
 
 
 
THC-COOH 
 
 
THC 
Ad libidum + daily at 8:00, 
16:00 and 24:00 to complete 
the collection period. 
 
 
 
 
 
 
 
 
 
30 min prior and 20–30 min 
following each exposure 
session with 16 cigs (only 1 
subject donated blood 
samples during the 4-cig 
exposure study)  
n = 882 (682 + 
200) 
 
 
 
 
 
 
 
 
 
 
55 blood samples 
(n = 16 cigs) and 
10 blood samples 
(n = 4 cigs) 
14 days for 16-
cig exposure 
study (n = 16 
cigs); 10 days for 
4-cig exposure 
study (n = 4 cigs) 
 
 
 
 
 
 
10 days (n = 16 
cigs) and 9 days 
(n  =4 cigs) 
< cut-off (n = 4 or 16 
cigs) 
 
 
 
0 ng/ml (n = 4 or 16 
cigs) 
 
 
0 ng/ml (n = 4 or 16 
cigs) 
 
0 ng/ml (n = 4 or 16 
cigs) 
Positive urines after 1st exposure 
session for 6 subjects (n = 16 
cigs) and 4/5 subjects over the 6-
day exposure (n = 4 cigs) 
 
≈75 ng/ml days 2–6 (n = 16 cigs) 
≈14.1 ng/ml days 2–6 (n = 4 cigs) 
 
 
30 ng/ml at day 4 (n = 16 cigs) 
almost 0 ng/ml (n = 4 cigs) 
 
7.3 ng/ml at day8 (n = 16 cigs)    
2.5 ng/ml at day6 (n = 4 cigs) 
Mule et al. (1988) 
Urine RIA 12 Cannabinoids 20–24 h after exposure 3 24 h < 6 ng/ml NA 
Palmieri et al. (1995) 
Urine (Study I) EMIT 
 
ADx 
20 
 
25 
THC 
 
THC 
Before exposure, 2, 12, and 
20 h and for next 6 mornings 
(44, 68, 92, 116, 140, and 
164h) 
27 urine samples 
164 h after 
exposure 
NA 
 
0 ng/ml 
8.5 ng/ml at 2 h 
 
5.7 ng/ml at 44 h 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
Urine (Study II) EMIT 
 
ADx 
20 
 
25 
THC 
 
THC 
Before exposure, 3, 7, and 
16h and for next 4 mornings 
(40, 64, 88, and 112h) 
21 urine samples 
112 h after 
exposure 
0 ng/ml 
 
0 ng/ml 
9.6 ng/ml at 7 h 
 
21.3 ng/ml at 7 h 
Niedbala et al. (2001) 
Oral fluid (OF) 
 
 
 
Urine 
EIA 
 
GC/MS/MS 
 
EIA 
 
GC/MS 
1 
 
0.5 
 
50 
 
15 
THC 
 
THC 
 
THC-COOH 
 
THC-COOH 
Prior to exposure and at 1, 2, 
4, 8, 16, 24, 48, and 72 h 
after marijuana administration 
 
Prior to exposure and at 1, 2, 
4, 8, 16, 24, 48, and 72 h 
after marijuana administration 
18 OF samples 
 
 
 
18 urine samples 
72 h following 
start of exposure 
Negative 
 
0 ng/ml 
 
9.7 ng/mld 
 
0 ng/ml 
Positive at 1h  
 
0 ng/ml 
 
3.2 ng/ml at 24 hd 
 
0 ng/ml 
Niedbala et al. (2004) 
Oral fluid (OF) 
 
 
 
 
Urine 
EIA 
 
GC/MS/MS 
 
 
EIA 
 
GC/MS/MS 
3 
 
0.75 
 
 
50 
 
1 
THC 
 
THC 
 
 
THC-COOH 
 
THC-COOH 
Before exposure and at 20, 
35, 50, 65, 95, 125, 155, 185, 
215, and 245 min after start of 
exposure 
 
Before exposure and at 20 
and 245 min after start of 
exposure. 
44 OF samples 
 
 
 
 
12 urine samples 
245 min 
 
 
 
 
245 min 
Negative 
 
0 ng/ml 
 
 
Negative 
 
0.9 ng/ml 
Positive at 20 min 
 
13.4 ng/ml at 20 min after start of 
exposure 
 
Negative 
 
0.9 ng/ml at 245 min after start of 
exposure 
Niedbala et al. (2005)  
Oral fluid (OF) 
(Study I) 
 
 
 
 
 
 
Urine (Study I) 
EIA 
 
 
GC/MS/MS 
 
 
 
 
EIA (EMIT) 
 
GC/MS/MS 
3 
 
 
0.75 
 
 
 
 
50 
 
1 
THC 
 
 
THC 
 
 
 
 
THC 
 
THC-COOH 
Before exposure and at 0 
(immediately at end of 
smoking), 15, 30, and 45 min 
(inside the van) and 1, 1.25, 
1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 
8, 10, 12, 24, 36, 48, 60, and 
72 h (outside of the van) 
 
Before exposure and at 1, 4, 
6, 8, 10, 12, 24, 36, 48, 60, 
and 72 h after start of 
exposure 
184 OF samples 
 
 
 
 
 
 
 
48 urine samples 
72 h 
 
 
 
 
 
 
 
72 h 
Negative 
 
 
≈ 0 ng/ml 
 
 
 
 
Negative 
 
1.2 ng/mld 
Positive at 0 and 15 min after 
exposure 
 
5.3 ng/ml immediately after 
exposure 
 
 
 
Negative 
 
8.4 ng/ml at 6 h after exposured 
Oral fluid (OF) 
(Study II) 
 
EIA 
 
GC/MS/MS 
3 
 
0.75 
THC 
 
THC 
Before exposure and at 0 
(immediately at end of 
smoking),15, 30, 45 min, 1, 
184 OF samples 
 
 
72 h 
 
 
Negative 
 
0 ng/ml 
Negative 
 
1 ng/ml at 1.5 h after exposure 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
 
 
 
 
Urine (Study II) 
 
 
 
 
EIA (EMIT) 
 
GC/MS/MS 
 
 
 
 
50 
 
1 
 
 
 
 
THC 
 
THC-COOH 
1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 
4, 6, 8, 10, 12, 24, 36, 48, 60, 
and 72 h (outside the van) 
 
Before exposure and at 1, 2, 
4, 6, and 8 h. 
 
 
 
 
24 urine samples 
 
 
 
 
8 h 
 
 
 
 
Negative 
 
7.3 ng/mld 
 
 
 
 
Negative 
 
8.9 ng/ml at 6 h after exposured 
Rohrich et al. (2010) 
Serum 
 
 
 
 
 
Urine 
ELISA 
 
 
GC/MS 
 
 
ELISA 
 
 
EIA 
 
 
GC/MS 
3 
 
 
0.5 
 
 
0.6 
 
 
25 
 
 
0.6 
 
 
1 
Cannabinoids 
 
 
THC 
 
 
THC-COOH 
 
 
Cannabinoids 
 
 
THC-COOH 
 
 
THC-COOH 
(hydrolyzed 
urine) 
Before exposure and at 1.5, 
3.5, 6, and 14 h after start of 
exposure 
 
 
 
Before exposure and at 3.5, 
6, 14, 36, 60, and 84 h after 
start of exposure. 
25 blood samples 
 
 
 
 
 
40 urine samples 
14 h 
 
 
 
 
 
84 h 
2 ng/ml 
 
 
0 ng/ml 
 
 
0.3 ng/ml 
 
 
1.4 ng/mld 
 
 
0 ng/ml 
 
 
0.4 ng/ml 
3 ng/ml at 3.5 h after start of 
exposure 
 
0.5 ng/ml at 1.5 h after start of 
exposure 
 
0.8 ng/ml at 3.5 h after start of 
exposure 
 
9.8 ng/ml at 6 h after start of 
exposured 
 
2.3 ng/ml at 14 h after start of 
exposure 
 
3.8 ng/ml at 14 h after start of 
exposure 
Schimmel et al. (2010) 
Blood (Serum) 
 
 
 
 
 
 
 
Urine 
EIA 
 
 
GC/MS 
 
 
 
 
EIA 
 
3 
 
 
1 
1 
8 
 
 
25 
 
Cannabinoids 
 
 
THC 
11-OH-THC 
THC-COOH 
 
 
Cannabinoids 
 
Before exposure and at 1.5, 
3.5, 6, and 14 h after start of 
exposure 
 
 
 
 
 
Before exposure and at 3.5, 
6, 14, 36, 60 and 84 h after 
16 
 
 
 
 
 
 
 
24 
14 h 
 
 
 
 
 
 
 
84 h 
Negative 
 
 
0 ng/ml 
0 ng/ml 
<LOD 
 
 
Negative 
 
Positive for 2 volunteers at 1.5 
and 3.5 h 
 
0 ng/ml  
0 ng/ml 
4 samples were > LOD (1 to 2 
ng/ml at 3.5–6 h) 
 
Negative 
 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
GC/MS 8 THC-COOH start of exposure 0 ng/ml 3.6 ng/ml at 6h and 3.7 ng/ml at 
14 h 
Moore et al. (2011) 
Oral fluid (OF) 
(Location 1) 
ELISA 
 
 
GC/MS 
 
 
 
 
 
Two-
dimensional 
GC-GC/MS 
4 
 
 
0.5 
 
0.5 
 
1 (CBD) 
 
0.002 
THC 
 
 
THC 
 
Cannabinol 
 
Cannabidiol 
 
THC-COOH 
Before exposure, at 20, 40, 
60, 120, and 180 min during 
passive exposure to 
marijuana (outside coffee 
shop), and between 12 and 
22 h (average 14.6 h) after 
leaving the coffee shop 
70 OF samples 180 min 
 
 
12–22 h 
> 4 ng/ml for 3 
subjects 
 
0.4 ng/ml 
 
0 ng/ml 
 
0 ng/ml 
 
0 ng/ml 
Positive over the 20 min to 3 h 
period 
 
4.3 ng/ml at 2 h 
 
0.7 ng/ml at 2 h 
 
0 ng/ml 
 
0 ng/ml 
Oral fluid (OF) 
(Location 2) 
ELISA 
 
 
 
GC/MS 
 
 
 
 
 
Two-
dimensional 
GC-GC/MS 
4 
 
 
 
0.5 
 
0.5 
 
1 (CBD) 
 
0.002 
THC 
 
 
 
THC 
 
Cannabinol 
 
Cannabidiol 
 
THC-COOH 
Before exposure, at 20, 40, 
60, 120, and 180 min during 
passive exposure to 
marijuana (outside the coffee 
shop), and between 12 and 
22 h (average 14.6 h) after 
leaving the coffee shop 
70 OF samples 180 min 
 
 
 
12–22 h 
THC: 
> 4 ng/ml for 3 
subjects 
 
0 ng/ml 
 
0 ng/ml 
 
0 ng/ml 
 
0 ng/ml 
Positive at the 3 h period 
 
 
 
7.5 ng/ml at 3 h 
 
0.9 ng/ml at 3 h 
 
0 ng/ml 
 
0 ng/ml 
Cone et al. (2014); Cone et al. (2015) 
Urine (Session I) 
 
 
 
 
 
 
 
GC/MS 
 
 
EMIT 
 
 
 
 
15 
 
 
20 
 
50 
 
 
THC-COOH 
 
 
THC 
 
Cannabinoids 
 
 
Before session, at end of 
exposure period, and at 0.25, 
1, 2, 3, 4 h, then for the 
following time intervals: 4–6, 
6–8, 8–10, 10–12, 12–22, 22–
26, 26–30, and 30–34 h 
(urine pooled for each 
subject) 
84 
 
 
 
 
 
 
 
30–34 h 
 
 
 
 
 
 
 
1.5 ng/mld 
 
 
29.7 ng/ml 
 
Negative 
 
 
22.4 ng/ml at 4–6 h after 
exposured 
 
86.5 ng/ml at 4–6h after exposure 
 
Negative 
 
 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
 
Oral Fluid (OF) 
(Session I) 
 
 
 
 
 
 
 
Whole blood 
(Session I) 
 
ELISA 
 
 
 
LC/MS/MS 
 
 
 
 
LC/MS/MS 
 
4 
 
 
 
2 
 
0.02 
 
 
0.5 
 
Cannabinoids 
 
 
 
THC 
 
THC-COOH 
(total) 
 
THC 
 
THC-COOH 
(free) 
 
11-OH-THC 
 
Immediately prior to each 
session and following 1-h 
exposure session at 0.25, 0.5, 
1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 
22, 26, 30, and 34 h after end 
of exposure 
 
 
 
Before session, at end of 1-h 
exposure session, and at 
0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 
8, 12, 22, 26, 30, and 34 h 
after end of each exposure 
session 
 
102 
 
 
 
 
 
 
 
 
96 h 
 
34 h 
 
 
 
 
 
 
 
 
34 h 
 
Negative 
 
 
 
0 ng/ml 
 
0 ng/ml 
 
 
0 ng/ml 
 
0 ng/ml 
 
 
0 ng/ml 
 
Positive at 15 min (all subjects); 
mean (range) 1.25 (0.25–3) h 
after exposure 
 
34 ng/ml at 0.25h 
 
0 ng/ml 
 
 
1.4 ng/ml at 0.25h 
 
1.2 ng/ml at 0.25h 
 
 
Negative 
Urine (Session II) 
 
 
 
 
 
 
 
Oral Fluid (OF) 
(Session II) 
 
 
 
 
 
 
 
Whole blood 
(Session II) 
GC/MS 
 
EMIT 
 
 
 
 
 
ELISA 
 
 
 
LC/MS/MS 
 
 
 
 
LC/MS/MS 
15  
 
20 
 
50 
 
 
 
4 
 
 
 
2 
 
0.02 
 
 
0.5 
THC-COOH 
 
THC 
 
Cannabinoids 
 
 
 
Cannabinoids 
 
 
 
THC 
 
THC-COOH 
(total) 
 
THC 
 
THC-COOH 
(free) 
Before session, at end of 
exposure period, at 0.25, 1, 2, 
3, 4 h, and then for following 
time intervals: 4–6, 6–8, 8–
10, 10–12, 12–22, 22–26, 26–
30, and 30–34 h (urine pooled 
for each subject) 
 
Immediately prior to each 
session and following 1-h 
exposure session at 0.25, 0.5, 
1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 
22, 26, 30, and 34 h  
 
 
 
 
Before session and following 
1-h exposure session at 0.25, 
0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 
22, 26, 30, and 34 h  
84 
 
 
 
 
 
 
 
102 
 
 
 
 
 
 
 
 
96 
30-34 h 
 
 
 
 
 
 
 
34 h 
 
 
 
 
 
 
 
 
34 h 
6.5 ng/mld 
 
44.8 ng/ml 
 
Negative 
 
 
 
Negative 
 
 
 
0 ng/ml 
 
0 ng/ml 
 
 
0 ng/ml 
 
0 ng/ml 
 
33.3 ng/ml at 4 h after exposured 
 
140 ng/ml at 4 h after exposure 
 
A single presumptive positive 
result at 4 h after exposure 
 
 
Positive at 15 min (all subjects); 
mean (range) 1.38 (0.25-3) h after 
exposure 
 
81.5 ng/ml at 0.25h 
 
0 ng/ml 
 
 
3.1 ng/ml at 0.25h 
 
2.5 ng/ml at 0.25h 
 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
 
11-OH-THC 
 
0 ng/ml 
 
Negative 
Urine (Session III) 
 
 
 
 
 
 
 
 
Oral Fluid (OF) 
(Session III) 
 
 
 
 
 
 
Whole blood 
(Session III) 
GC/MS 
 
EMIT 
 
 
 
 
 
 
ELISA 
 
 
LC/MS/MS 
 
 
 
 
LC/MS/MS 
15 
 
20 
 
 
50 
 
 
 
4 
 
 
2 
 
0.02 
 
 
0.5 
THC-COOH 
 
THC 
 
 
Cannabinoids 
 
 
 
Cannabinoids 
 
 
THC 
 
THC-COOH 
(total) 
 
THC 
 
THC-COOH 
(free) 
 
11-OH-THC 
Before session, at end of 
exposure period, and at 0.25, 
1, 2, 3, 4 h, then for the 
following time intervals: 4–6, 
6–8, 8–10, 10–12, 12–22, 22–
26, 26–30, and 30–34 h 
(urine pooled for each 
subject) 
 
Immediately prior to each 
session and following the 1-h 
exposure session at 0.25, 0.5, 
1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 
22, 26, 30 and 34 h  
 
 
 
Before session and following 
the 1-h exposure session at 
0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 
8, 12, 22, 26, 30, and 34 h  
84 
 
 
 
 
 
 
 
 
102 
 
 
 
 
 
 
 
96 
30-34 h 
 
 
 
 
 
 
 
 
34 h 
 
 
 
 
 
 
 
34 h 
1.4 ng/mld 
 
26.3 ng/ml 
 
 
Negative 
 
 
 
Negative 
 
 
0 ng/ml 
 
0 ng/ml 
 
 
0 ng/ml 
 
0 ng/ml 
 
 
0 ng/ml 
8.61 ng/ml at 4 h after exposured 
 
55.2 ng/ml at 4–6 h after 
exposure 
 
Negative 
 
 
 
Mean (range) 0.38 (0.25–1.5) h 
after exposure 
 
16.9 ng/ml at 0.25h 
 
0 ng/ml 
 
 
0.5 ng/ml at 0.25 h 
 
0.2 ng/ml at 0.25 h 
 
 
Negative 
Moosmann et al. (2014) 
Hair 
 
 
 
 
 
 
 
 
 
Urine 
LC/MS/MS 
 
 
 
 
 
 
 
 
 
EMIT 
NA 
 
 
20 
pg/mg 
 
20 
pg/mg 
 
 
10 
THC-A 
 
 
THC 
 
 
Cannabinol 
 
 
 
THC-COOH 
Before exposure period, 2 
strands every week after the 
weekend (shortly before 
exposure to joint), and 2 
strands 4 weeks after the 
exposure period. One 
participant gave 4 strands for 
seven weeks after the 
exposure period 
 
Before exposure period, and 
30 strands of hair 
from various 
regions of the 
head 
 
 
 
 
 
 
NA 
4 weeks after 
exposure for two 
participants and 
7 weeks after 
exposure for one 
participant 
 
 
 
 
NA 
0 pg/mg 
 
 
50 pg/mg 
 
 
36.7 pg/mg 
 
 
 
0 ng/ml 
17.3 pg/mg at the end of 
exposure period 
 
803 pg/mg at the end of exposure 
period 
 
307 pg/mg at the end of exposure 
period 
 
 
0 ng/ml 
Body fluid Analytical 
method 
Cut-off 
(ng/ml) 
Substances 
analyzed 
Sampling scenario Total number of 
samples 
Last sample 
collection 
Value of last 
collected samples 
Maximum concentration 
obtained after exposurea 
twice a week 
 
ADx, Abbott automated method; Cigs, cigarettes; EIA, Enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; EMIT, enzyme multiplied immunoassay technique; 
GC/MS: Gas chromatography–mass spectrometry; LC/MS/MS, liquid chromatography–tandem mass spectrometry; NA, Information not available; RIA, Radioimmunoassay; THC, 
Δ9-tetrahydrocannabinol; THC-A, Δ9-tetrahydrocannabinolic acid A; THC-COOH, 11-nor-delta-9-THC-carboxylic acid; 11-OH-THC,11-hydroy-delta-9-THC. 
 
a The maximal concentration obtained in calculating a mean between the non-smoker values at a specific time. 
b In study I, volunteers were passively exposed to hashish smoke. 
c In study II, volunteers were passively exposed to marijuana smoke. 
d Urine values were adjusted for creatinine. 
Table 2 Summary of the exposure scenarios of studies on the passive inhalation of cannabis smoke 
Exposure 
area’s 
volume (L) 
Room 
type 
Room 
ventilation 
Substanc
e 
Smoking 
mode 
Exposure 
smoke type 
Protective 
equipment 
used 
Specific 
exposure 
conditions 
Placebo 
exposure 
Non-
smoking 
subject 
exposed 
Gender Age 
(years) 
Exposure 
time (min) 
Total 
exposure 
number 
Exposure 
time period 
No. of 
cannabis 
cigarettes 
smoked 
THC 
dose 
(mg) 
Perez-Reyes et al. (1983) 
15,500a Small 
room 
Unventilated Marijuana Smokers 
(n = 4)b 
Sidestream None None None 2 3 F / 3 M NA 60 1 NA 8b 46 
15,500a Small 
room 
Unventilated Marijuana Smokers 
(n = 4)c 
Sidestream None None None 2 3 F / 3 M NA 60 1 NA 8c 52 
3,500 Station 
wagon 
Unventilated Marijuana Smokers 
(n = 4)c 
Sidestream None None None 2 3 F / 3 M NA 60 1 NA 8c 52 
15,500 Small 
room 
Unventilated Marijuana Smokers 
(n = 4)d 
Sidestream None None None 2 3 F / 3 M NA 60 3 NA 4d 105 
Mason et al.(1983) 
15,500 Small 
room 
unventilated Marijuana Smokers 
(n = 4)e 
Sidestream None All analyses 
were 
performed 
blind 
None 3f Males NA 60 1 NA 4e 105 
Law et al. (1984) 
27,950 small 
office 
Unventilatedg Cannabis 
resin 
Smokers 
(n = 6)h 
Sidestream None None None 4 Males NA 180 1 NA 6h 103 
Morland et al.(1985) 
1,650 Small car NA Hashish Smokers 
(n = 3) 
Sidestream None None None 2 3 F / 7 
Mi 
35–50 30 1 NA 6 90 
1,650 Small car NA Marijuana Smokers 
(n = 2) 
Sidestream None None None 3 3 F / 7 
Mi 
35–50 30 1 NA 12 90 
Cone and Johnson (1986); Cone et al. (1987a); Cone et al. (1987b) 
≈12,226j Closed 
ward 
under 
close 
surveillan
ce 
Small 
unventilated 
room 
Marijuana Machine Only 
sidestream 
smoke 
(mainstrea
m was 
removed) 
Gogglesk 
Not allowed 
to drink or 
eat during 
exposure 
sessions. 
At rest. 
Double-
blind 
conditions 
to the 
smoke 
Yesl 5 (healthy 
drug-free 
with a 
history of 
Marijuana 
use) 
Males 22, 26, 
33, 40 
and 54 
60 12     (6 
consecutive 
days per 
exposure) 
Morning 
(8:30 to 
9:30 am) 
16m 393.98n 
≈12,226j Closed 
ward 
under 
close 
surveillan
ce 
Small 
unventilated 
room 
Marijuana Machine Only 
sidestream 
smoke 
(mainstrea
m was 
removed) 
Gogglesk 
Not allowed 
to drink or 
eat during 
exposure 
sessions. 
At rest 
Without 
blind 
conditions 
None 2 (healthy 
drug-free 
with no 
history of 
Marijuana 
use, from 
staff) 
Males 37 and 
42 
60 6 
(6 
consecutive 
days) 
Morning 
(8:30 to 
9:30 am) 
16 2.8% Δ-
9-THC 
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Exposure 
area’s 
volume (L) 
Room 
type 
Room 
ventilation 
Substanc
e 
Smoking 
mode 
Exposure 
smoke type 
Protective 
equipment 
used 
Specific 
exposure 
conditions 
Placebo 
exposure 
Non-
smoking 
subject 
exposed 
Gender Age 
(years) 
Exposure 
time (min) 
Total 
exposure 
number 
Exposure 
time period 
No. of 
cannabis 
cigarettes 
smoked 
THC 
dose 
(mg) 
Mule et al (1988) 
21,600 room Windowless Marijuana Smokers 
(n = 8) 
Sidestream None None None 3 Males NA 60 1 NA 4 108 
Palmeri et al. (1995) 
30,780 room unventilated Hashish machine Sidestream None None None 3 2 F / 2 M 30–50 60 1 NA 3 45 
3,000 Car Car windows 
closed 
Hashish machine Sidestream None None None 3 2 F / 2 M 30–50 30 1 NA 2 30 
Niedbala et al. (2001) 
≈133,960 Room No central 
ventilation 
system, but 
windows were 
opened 
occasionally 
to relieve the 
smoky 
atmosphere 
Marijuana Smokers 
(n = 10)p 
Sidestream None Drinking 
beer or 
soda during 
exposure 
was 
allowed. 
Food 
(pizza) was 
available 
after first  
2 h of 
specimen 
collectionq 
None 2 (control 
subjects) 
Males 32 and 
39 
240 1 NA 10p NA 
Niedbala et al. (2004) 
36,000 Room A closed room 
with all door 
and window 
openings 
sealed 
Marijuana Smokers 
(n = 5)r 
Sidestream None 
No drinking 
allowed for 
first 60 min. 
Located 
approx.. 
1.5 m from 
smokers 
None 4 Males 37–49 240 (4h) 1 NA 5r NA 
Niedbala et al. (2005) 
Study 1 
15,300 
Motor 
vehicle (8 
passenge
rs) 
Unventilated 
(doors and 
windows 
closed, and 
engine turned 
off) 
Marijuana Smokers 
(n = 4)s 
Sidestream None Seatt None 4 Males 34–50 60 1 NA 4s 158s 
Study 2 
15,300 
Motor 
vehicle (8 
passenge
rs) 
Unventilated 
(doors and 
windows 
closed, and 
engine turned 
off) 
Marijuana Smokers 
(n = 4)u 
Sidestream None Seatt None 4 Males 25–50 60 1 NA 4u 333u 
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Exposure 
area’s 
volume (L) 
Room 
type 
Room 
ventilation 
Substanc
e 
Smoking 
mode 
Exposure 
smoke type 
Protective 
equipment 
used 
Specific 
exposure 
conditions 
Placebo 
exposure 
Non-
smoking 
subject 
exposed 
Gender Age 
(years) 
Exposure 
time (min) 
Total 
exposure 
number 
Exposure 
time period 
No. of 
cannabis 
cigarettes 
smoked 
THC 
dose 
(mg) 
Rohrich et al. (2010) 
200,000 Coffee 
shop 
(large 
room) 
No windows 
but relatively 
efficient 
ventilation; not 
very smoky 
during the 
exposure 
period. 
Cannabis 
cigarettes 
Additional 
8 g 
hashish 
and 
marijuana 
was 
burned 
down by 
the 
volunteer
s in an 
ashtray 
about 1.5 
m away 
from 
them. 
Smokers 
(n = 8 to 
25) 
stayed 
around 15 
min, but 
some up 
to 1h. Not 
less than 
1 m from 
passive 
smokers, 
mostly 5 
to 6 m 
away. 
Sidestream None Volunteers 
sat together 
at a table 
almost in 
middle of 
room. Each 
volunteer 
consumed 2 
to 3 cans 
(0.33 L) of 
soft drinks 
(no food) 
None 8 4 F / 4 M 28–49 180 1 NA 8–25 
smoking 
guestsv 
v 
Schimmel et al. (2010) 
200,000 Coffee 
shop 
Yes (no 
window) 
Hashish 
and 
marijuana 
Smokers 
(n = 8 to 
25) 
Sidestream NA NA None 8 4 F / 4 M 27–59 180 1 NA NA 8 g of 
hashish 
and 
marijuan
a were 
burnt 
Moore et al. (2011) 
Place 1: 
122,500 
Coffee 
shop 
(large 
room) 
NA Marijuana Smokers 
(n = 4 to 
16; mean: 
8) 
Sidestream None NA None 10 3 F / 2 M 22.5–
23 
180 1 NA 4–16 
active 
smokers 
NA 
Place 2: 
42,000 
Coffee 
shop 
(small 
room) 
NA Marijuana Smokers 
(n = 0 to 
6; mean: 
2.5) 
Sidestream None NA None 10 3 F / 2 M 23–25 180 1 NA 0–6 active 
smokers 
NA 
Cone et al. (2014, 2015) 
≈ 25,726 Exposure 
chamberw 
Unventilated Cannabis Smokersx Sidestream Goggles Non-
smokers 
remained in 
their 
assigned 
None 6 9 F / 9 M 
in total 
Av. age 
28 (7x 
20–45)  
60 1 NA Ad libitum 5,3%x 
≈ 25,726 Exposure 
chamberw 
Unventilated 
(the door was 
opened briefly 
Cannabis Smokersy Sidestream Goggles None 6 60 1 NA Ad libitum 11,3%y 
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Exposure 
area’s 
volume (L) 
Room 
type 
Room 
ventilation 
Substanc
e 
Smoking 
mode 
Exposure 
smoke type 
Protective 
equipment 
used 
Specific 
exposure 
conditions 
Placebo 
exposure 
Non-
smoking 
subject 
exposed 
Gender Age 
(years) 
Exposure 
time (min) 
Total 
exposure 
number 
Exposure 
time period 
No. of 
cannabis 
cigarettes 
smoked 
THC 
dose 
(mg) 
for exit and 
entry) 
seats. 
Not allowed 
to eat or 
drink during 
or after 
session until 
after first 
oral fluid 
specimen 
collected. 
≈ 25,726 Exposure 
chamberw 
Ventilated 
(comparable 
to home air-
conditioning 
(11.2 air 
changes per 
hour) 
Cannabis Sidestream Goggles None 6 60 1 NA Ad libitum 11,3%y 
Moosmann et al. (2014) 
12,500 Room NA Marijuana Water-jet 
vacuum 
pump 
Sidestream Smoke 
inhalation 
excluded by 
breathing 
compressed 
air through 
SCUBA 
regulators 
Non-
smokers sat 
in a circle 
facing each 
other. Joint 
held in front 
participant’s 
mouth for 
10–15 s, 
then 
connected 
to vacuum 
for one puff, 
then passed 
on to next 
participant 
None 3 NA NA 15–20 
minutes 
(one joint) 
every 
weekday for 
3 weeks 
15 Morning 1 every 
weekday 
for 3 
weeks 
500 mg 
of 
marijuan
a flowers 
containin
g 9.2% 
THCz 
F, female; M, males; NA, information not available. 
 
a The volume of solid furniture present in the room was subtracted from the total room volume. 
b Each smoker smoked 2 marijuana cigarettes containing 2.5% of THC. 
c Each smoker smoked 2 marijuana cigarettes containing 2.8% of THC. 2.8% is the highest potency marijuana cigarette available from NIDA (National Institute on Drug Abuse). 
d Each smoker smoked 4 marijuana cigarettes containing 2.8% of THC daily for 3 consecutive days. 2.8% is the highest potency marijuana cigarette available from NIDA. 
e Each cigarette contained 26.2 mg of THC. 
f Two non-smokers participated at the beginning of exposure; on the second day of study, a third passive smoker participated. 
g The single door was opened and closed approximately 18 times during the experiment to allow access to the subjects. 
h Cigarettes contained an average of 175 mg resin, equivalent to 17.1 mg THC per cigarette. The smoking period lasted 10–34 min. 
i No information about the gender repartition between studies. 
j Volume adjusted for contents and the presence of 5 volunteers. 
k To minimize eye irritation and to prevent color discrimination between placebo and active cigarettes. 
l Before and after marijuana exposure, exposure to 16 placebo cigarettes in the same conditions for 2 days (1st exposure) and 1 day (2nd exposure) to 4 placebo cigarettes. 
m 8 cigarettes burnt from 8:30 to 8:45 am; and from 9:00 to 9:15 am 8 others for the 1st exposure; 4 cigarettes (and not 8) burnt for the 2nd exposure using the same exposure pattern. 
n Cigarettes had an average weight of 877±20 mg. 
o There were in total 4 volunteers including 2 females and 2 males, and 3 of them have participated in each study. 
p Cigarettes contained an average of 20–25 mg THC. The smoking period was 20–30 min. 
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q Collection of oral fluid specimens was preceded by a 10-min "time-out" period (no eating or drinking). 
r Joints contained an average of 1.75% THC per cigarette (≈ 12.75 mg of THC). The smoking period was 20 min. 
s Joints contained an average of 5.4% THC per cigarette (≈ 39.5 mg of THC mixed with tobacco). The smoking period was 20 min. 
t One cannabis smoker sat on each row alongside one passive subject. 
u Joints contained an average of 10.9% THC per cigarette (≈ 83.2 mg pure THC). The smoking period was 20 min. 
v The exact number of joints smoked during the 3 h period and the average THC content of the cannabis cigarettes is unknown. Additionally, 8 g of both hashish and marijuana was burned by the 
volunteers in an ashtray about 1.5 m away from them. 
w A specially designed smoking chamber made of Plexiglas walls and aluminum supports was built for this experiment. 
x The lower potency cannabis cigarettes were machine rolled to 85 mm in length, 25 mm in circumference, and weighed a mean 0.92 g/cigarette (SD = 0.06); the cigarettes had an assayed mean content 
of cannabinoids as follows: 5.3% (0.48%) total THC, 0.01% (0.0%) CBD, and 0.35% (0.04%) CBN. 
y The higher potency cigarettes were hand-rolled to 70 mm in length (24.5 mm) and had a mean weight of 1.0 g/cigarette (SD = 0.04); the cigarettes had an assayed mean content (n = 12 for THC; n = 4 
for other cannabinoids) of cannabinoids as follows: 11.3% (0.29%) total THC, 0.08% (0.12%) CBD, and 0.76% (0.06%) CBN. 
z Each day, one joint was prepared using 500 mg marijuana flowers with a total THC content of 9.2% and 500 mg tobacco. 
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